Orthofix Medical Inc. (OFIX)
Lewisville, TX, US
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| SeaSpine Holdings Corporation | SPNE | 2022-11-08 | View |
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.37% | -0.33% | -1.62% | -8.21% | -20.39% | -19.66% | -2.01% | -33.00% | -69.85% | -71.56% | +16.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
18.00
+63.0%
|
| Last Year | 3 |
19.33
+75.1%
|
| All Time | 5 |
22.60
+104.7%
|
-
Revenue growth Medical - Devices: +11.2%+2.9% Q1'26: +1.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+30.9% ★ Q1'26: +61.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-11.8% Q1'26: -14.4% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-8.9% Q1'26: -7.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-12.3% Q1'26: -10.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+4.6% Q1'26: +3.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-10.26× Q1'26: -303.61× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. |
Dec 2030 3 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
545.64M
est: 455.12M (+19.9%)
|
564.37M
est: 443.80M (+27.2%)
|
578.99M
est: 677.29M (-14.5%)
|
462.32M
est: 430.03M (+7.5%)
|
396.49M
est: 396.00M (+0.1%)
|
409.79M
est: 407.99M (+0.4%)
|
433.82M
est: 433.80M (+0.0%)
|
453.04M
est: 453.38M (-0.1%)
|
459.96M
est: 461.45M (-0.3%)
|
406.56M
est: 407.00M (-0.1%)
|
464.48M
est: 464.00M (+0.1%)
|
460.71M
est: 542.12M (-15.0%)
|
746.64M
est: 771.65M (-3.2%)
|
799.49M
est: 796.50M (+0.4%)
|
822.31M
est: 814.43M (+1.0%)
|
854.43M
853.26M – 855.48M
+4.9% YoY
|
906.25M
905.14M – 906.86M
+6.1% YoY
|
958.48M
953.90M – 960.54M
+5.8% YoY
|
1.03B
1.03B – 1.03B
+7.7% YoY
|
1.09B
1.08B – 1.09B
+5.3% YoY
|
| EBITDA |
87.19M
est: 69.93M (+24.7%)
|
112.15M
est: 80.65M (+39.1%)
|
53.27M
est: 47.01M (+13.3%)
|
96.19M
est: 99.84M (-3.7%)
|
29.92M
est: -8.48M (+452.7%)
|
39.87M
est: 14.61M (+172.9%)
|
60.94M
est: 51.72M (+17.8%)
|
41.54M
est: 36.56M (+13.6%)
|
1.55M
est: -2.24M (+169.2%)
|
36.39M
est: 45.35M (-19.8%)
|
21.44M
est: 36.60M (-41.4%)
|
15.66M
est: 2.22M (+606.7%)
|
-79.49M
est: -14.86M (-435.1%)
|
-34.18M
est: -15.33M (-122.9%)
|
-22.35M
est: -15.68M (-42.6%)
|
-16.45M
-16.47M – -16.43M
-4.9% YoY
|
-17.45M
-17.46M – -17.43M
-6.1% YoY
|
-18.45M
-18.49M – -18.36M
-5.8% YoY
|
-19.87M
-19.91M – -19.77M
-7.7% YoY
|
-20.92M
-20.96M – -20.82M
-5.3% YoY
|
| EBIT |
64.84M
est: 51.92M (+24.9%)
|
89.63M
est: 65.11M (+37.7%)
|
30.49M
est: 29.38M (+3.8%)
|
76.17M
est: 85.02M (-10.4%)
|
9.26M
est: -7.59M (+221.9%)
|
35.44M
est: 16.85M (+110.3%)
|
40.81M
est: 38.47M (+6.1%)
|
22.89M
est: 27.04M (-15.4%)
|
-26.93M
est: -23.04M (-16.9%)
|
2.12M
est: -10.29M (+120.6%)
|
-11.66M
est: -21.71M (+46.3%)
|
-16.42M
est: -39.14M (+58.1%)
|
-140.05M
est: -70.27M (-99.3%)
|
-94.24M
est: -72.54M (-29.9%)
|
-73.32M
est: -74.17M (+1.1%)
|
-77.81M
-77.91M – -77.71M
-4.9% YoY
|
-82.53M
-82.59M – -82.43M
-6.1% YoY
|
-87.29M
-87.48M – -86.87M
-5.8% YoY
|
-93.98M
-94.19M – -93.54M
-7.7% YoY
|
-98.95M
-99.16M – -98.47M
-5.3% YoY
|
| Net Income |
24.47M
est: 19.73M (+24.0%)
|
44.21M
est: 32.39M (+36.5%)
|
-1.07M
est: -2.58M (+58.4%)
|
51.30M
est: 49.35M (+3.9%)
|
-2.81M
est: -21.10M (+86.7%)
|
3.06M
est: 2.45M (+24.8%)
|
6.22M
est: 5.09M (+22.2%)
|
13.81M
est: 12.32M (+12.1%)
|
-28.46M
est: -34.93M (+18.5%)
|
2.52M
est: -4.76M (+152.9%)
|
-38.38M
est: -65.31M (+41.2%)
|
-19.75M
est: 16.99M (-216.3%)
|
-151.40M
est: -127.94M (-18.3%)
|
-126.00M
est: -112.74M (-11.8%)
|
-92.19M
est: -89.98M (-2.5%)
|
-44.59M
-44.79M – -44.39M
+50.4% YoY
|
-32.45M
-32.60M – -32.30M
+27.2% YoY
|
-11.75M
-11.80M – -11.69M
+63.8% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
304.81M
est: 240.30M (+26.8%)
|
319.57M
est: 225.59M (+41.7%)
|
320.08M
est: 348.16M (-8.1%)
|
254.17M
est: 257.87M (-1.4%)
|
265.24M
est: 264.72M (+0.2%)
|
255.69M
est: 199.58M (+28.1%)
|
272.76M
est: 258.11M (+5.7%)
|
290.03M
est: 249.07M (+16.4%)
|
309.28M
est: 380.18M (-18.6%)
|
272.38M
est: 347.18M (-21.5%)
|
290.67M
est: 310.18M (-6.3%)
|
308.78M
est: 362.40M (-14.8%)
|
530.40M
est: 498.10M (+6.5%)
|
532.53M
est: 514.13M (+3.6%)
|
456.39M
est: 525.71M (-13.2%)
|
551.53M
550.78M – 552.21M
+4.9% YoY
|
584.98M
584.26M – 585.37M
+6.1% YoY
|
618.69M
615.74M – 620.02M
+5.8% YoY
|
666.15M
662.97M – 667.58M
+7.7% YoY
|
701.33M
697.98M – 702.84M
+5.3% YoY
|
| EPS |
1.43
est: 1.01 (+42.3%)
|
2.51
est: 1.55 (+62.5%)
|
-0.06
est: 2.44 (-102.4%)
|
2.70
est: 2.80 (-3.6%)
|
-0.15
est: 0.75 (-120.0%)
|
0.17
est: 1.42 (-88.1%)
|
0.34
est: 1.61 (-78.9%)
|
0.75
est: 1.73 (-56.7%)
|
-1.51
est: 1.55 (-197.3%)
|
0.13
est: -0.03 (+519.6%)
|
-1.95
est: 0.76 (-355.5%)
|
-0.98
est: 0.45 (-320.2%)
|
-4.12
est: -3.21 (-28.2%)
|
-3.30
est: -2.83 (-16.5%)
|
-2.28
est: -2.26 (-0.9%)
|
-1.12
-1.12 – -1.11
+50.4% YoY
|
-0.82
-0.82 – -0.81
+27.2% YoY
|
-0.30
-0.30 – -0.29
+63.8% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David Rosen | 3.67M | 9.97% | — | 3.67M | — | — | IN | — | 2024-02-12 | ↗ |
| 2 | LP | 3.67M | 9.97% | — | 3.67M | — | — | IA, PN | — | 2024-02-12 | ↗ |
| 3 | Armistice Capital, LLC | 3.60M | 9.79% | — | 3.60M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 4 | Steven Boyd | 3.60M | 9.79% | — | 3.60M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 5 | (1) BlackRock, Inc. | 3.39M | 17.20% | 3.35M | — | 3.39M | — | HC | Delaware | 2022-01-27 | ↗ |
| 6 | (1)Names of reporting persons. BlackRock, Inc. | 3.09M | 16.00% | 3.06M | — | 3.09M | — | HC | Delaware | 2021-01-25 | ↗ |
| 7 | ARNAUD AJDLER | 2.69M | 7.30% | — | — | 2.69M | — | IN | — | 2023-11-03 | ↗ |
| 8 | ENGINE CAPITAL MANAGEMENT GP, LLC | 2.69M | 7.30% | — | — | 2.69M | — | OO | — | 2023-11-03 | ↗ |
| 9 | ENGINE CAPITAL MANAGEMENT, LP | 2.69M | 7.30% | — | — | 2.69M | — | PN | — | 2023-11-03 | ↗ |
| 10 | Orthofix Holdings, Inc. | 2.65M | 6.00% | — | 2.65M | — | — | CO | Curacao | 2018-04-03 | ↗ |
| 11 | Orthofix International N.V. | 2.65M | 6.00% | — | 2.65M | — | — | CO | Curacao | 2018-04-03 | ↗ |
| 12 | 14-1770168 | 2.56M | 6.69% | 2.56M | — | 2.56M | — | IA | — | 2024-11-13 | ↗ |
| 13 | ENGINE INVESTMENTS, LLC | 2.46M | 6.70% | — | — | 2.46M | — | OO | — | 2023-11-03 | ↗ |
| 14 | ENGINE CAPITAL, L.P. | 2.20M | 6.00% | — | — | 2.20M | — | PN | — | 2023-11-03 | ↗ |
| 15 | The Vanguard Group - 23-1945930 | 2.13M | 10.79% | — | 15.4K | 2.10M | 31.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 16 | Morgan Stanley | 2.06M | 5.60% | — | 2.03M | — | 13.00 | HC, CO | — | 2024-02-09 | ↗ |
| 17 | Morgan Stanley Capital Services LLC | 1.91M | 5.20% | — | — | — | 13.00 | BD, CO | — | 2024-02-09 | ↗ |
| 18 | Capital Research Global Investors ** | 1.29M | 6.60% | 1.29M | — | — | — | IA | Delaware | 2013-11-08 | ↗ |
| 19 | Stephen DuBois | 1.20M | 6.50% | — | 1.20M | — | 1.20M | IN | Stephen DuBois United States | 2014-09-30 | ↗ |
| 20 | 04-2683227 | 1.14M | 5.86% | — | 926.8K | — | — | IA | Massachusetts | 2014-02-14 | ↗ |
| 21 | SEGALL BRYANT & HAMILL, LLC | 1.00M | 5.33% | — | — | — | — | IA | Delaware | 2015-05-14 | ↗ |
| 22 | Conan Laughlin | 1.00M | 5.30% | — | 1.00M | — | 1.00M | IN | Cayman Islands | 2016-01-22 | ↗ |
| 23 | North Tide Capital, LLC | 1.00M | 5.30% | — | 1.00M | — | 1.00M | OO | Cayman Islands | 2016-01-22 | ↗ |
| 24 | Paradice Investment Management LLC | 991.9K | 5.00% | — | 621.7K | — | — | IA | Delaware | 2022-02-10 | ↗ |
| 25 | Paradice Investment Management Pty Ltd | 991.9K | 5.00% | — | 621.7K | — | — | HC | Delaware | 2022-02-10 | ↗ |
| 26 | North Tide Capital Master, LP | 915.0K | 4.80% | — | 915.0K | — | 915.0K | PN | Cayman Islands | 2016-01-22 | ↗ |
| 27 | ENGINE JET CAPITAL, L.P. | 264.9K | 1.00% | — | — | 264.9K | — | PN | — | 2023-11-03 | ↗ |
| 28 | ENGINE INVESTMENTS II, LLC | 227.6K | 1.00% | — | — | 227.6K | — | OO | — | 2023-11-03 | ↗ |
| 29 | ENGINE LIFT CAPITAL, LP | 227.6K | 1.00% | — | — | 227.6K | — | PN | — | 2023-11-03 | ↗ |
| 30 | Consonance Capital Management LP | 10.00 | 12.00% | — | — | — | — | IA, PN | Delaware USA | 2017-02-13 | ↗ |
| 31 | Consonance Capman GP LLC | 10.00 | 12.00% | — | — | — | — | HC, OO | Delaware USA | 2017-02-13 | ↗ |
| 32 | Mitchell Blutt | 10.00 | 12.00% | — | — | — | — | HC, IN | Delaware USA | 2017-02-13 | ↗ |
| 33 | #80-0175963 | — | 0.00% | — | — | — | — | IA | Massachusetts | 2014-02-07 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 10.8K +10.8K (+100.0%) | 163.83M +163.8M (+100.0%) | 0.03% +0.027 pp | 0.06% +0.065 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 2 | ENGINE CAPITAL MANAGEMENT, LP | 4.25M +— (+0.0%) | 64.47M +2.2M (+3.6%) | 10.69% -0.072 pp | 8.90% +1.509 pp | USD13.42 +13.0% | 9 qtrs — |
| 3 | RUBRIC CAPITAL MANAGEMENT LP | 3.72M +— (+0.0%) | 56.42M +1.9M (+3.6%) | 9.36% -0.063 pp | 0.67% +0.060 pp | USD15.51 -2.3% | 12 qtrs — |
| 4 | JUNIPER INVESTMENT COMPANY, LLC | 3.51M +663.3K (+23.3%) | 53.22M +11.5M (+27.7%) | 8.83% +1.620 pp | 18.30% +2.354 pp | USD15.36 -1.3% | 7 qtrs — |
| 5 | PARADIGM CAPITAL MANAGEMENT INC/NY | 3.30M -39.6K (-1.2%) | 50.10M +1.1M (+2.3%) | 8.31% -0.156 pp | 2.11% -0.014 pp | USD12.90 +17.5% | 12 qtrs — |
| 6 | BLACKROCK, INC. | 3.14M +2.3K (+0.1%) | 47.60M +1.7M (+3.6%) | 7.90% -0.047 pp | 0.00% +0.000 pp | USD15.41 -1.6% | 6 qtrs — |
| 7 | ARMISTICE CAPITAL, LLC | 2.65M +412.0K (+18.4%) | 40.14M +7.4M (+22.6%) | 6.66% +0.998 pp | 0.48% -0.008 pp | USD16.30 -7.0% | 13 qtrs — |
| 8 | VANGUARD GROUP INC | 2.30M +22.3K (+1.0%) | 34.94M +1.5M (+4.6%) | 5.80% +0.018 pp | 0.00% +0.000 pp | USD34.12 -55.6% | 30 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 1.44M -34.5K (-2.3%) | 21.85M +245.1K (+1.1%) | 3.62% -0.112 pp | 0.01% +0.000 pp | USD12.88 +17.7% | 9 qtrs — |
| 10 | PHILOSOPHY CAPITAL MANAGEMENT LLC | 1.02M +131.6K (+14.9%) | 15.39M +2.5M (+19.0%) | 2.55% +0.316 pp | 0.70% +0.171 pp | USD13.69 +10.7% | 4 qtrs — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 949.1K -193.5K (-16.9%) | 14.39M -2.3M (-14.0%) | 2.39% -0.506 pp | 0.00% -0.001 pp | USD19.42 -21.9% | 30 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 947.2K +5.9K (+0.6%) | 14.36M +578.4K (+4.2%) | 2.38% -0.001 pp | 0.00% +0.000 pp | USD29.33 -48.3% | 31 qtrs — |
| 13 | STATE STREET CORP | 857.7K -14.4K (-1.7%) | 13.00M +234.5K (+1.8%) | 2.16% -0.051 pp | 0.00% +0.000 pp | USD32.19 -52.9% | 30 qtrs — |
| 14 | AYAL CAPITAL ADVISORS LTD | 742.4K -87.5K (-10.5%) | 11.25M -895.4K (-7.4%) | 1.87% -0.234 pp | 3.92% -0.860 pp | USD12.52 +21.1% | 9 qtrs — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 333.8K -2.0K (-0.6%) | 5.06M +144.4K (+2.9%) | 0.84% -0.011 pp | 0.00% +0.000 pp | USD26.37 -42.5% | 30 qtrs — |
| 16 | NUVEEN, LLC | 332.0K -203.2K (-38.0%) | 5.03M -2.8M (-35.8%) | 0.84% -0.520 pp | 0.00% -0.001 pp | USD14.88 +1.9% | 4 qtrs — |
| 17 | NORTHERN TRUST CORP | 318.6K -25.0K (-7.3%) | 4.83M -200.8K (-4.0%) | 0.80% -0.069 pp | 0.00% +0.000 pp | USD34.37 -55.9% | 30 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 261.4K -34.9K (-11.8%) | 3.96M -374.5K (-8.6%) | 0.66% -0.093 pp | 0.00% +0.000 pp | USD12.10 +25.3% | 30 qtrs — |
| 19 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 256.1K -54.6K (-17.6%) | 3.88M -665.5K (-14.6%) | 0.64% -0.142 pp | 0.00% -0.001 pp | USD14.71 +3.1% | 5 qtrs — |
| 20 | JPMORGAN CHASE & CO | 237.3K -20.8K (-8.0%) | 3.60M -180.6K (-4.8%) | 0.60% -0.057 pp | 0.00% +0.000 pp | USD15.96 -5.0% | 30 qtrs — |
| 21 | GABELLI FUNDS LLC | 235.3K +1.0K (+0.4%) | 3.57M +137.0K (+4.0%) | 0.59% -0.001 pp | 0.02% +0.001 pp | USD34.26 -55.8% | 30 qtrs — |
| 22 | ACADIAN ASSET MANAGEMENT LLC | 226.6K +56.2K (+33.0%) | 3.43M +941.0K (+37.8%) | 0.57% +0.139 pp | 0.01% +0.001 pp | USD14.96 +1.3% | 30 qtrs — |
| 23 | MORGAN STANLEY | 224.6K +52.2K (+30.3%) | 3.41M +881.6K (+34.9%) | 0.56% +0.129 pp | 0.00% +0.000 pp | USD14.93 +1.5% | 30 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 211.4K -73.5K (-25.8%) | 3.21M -965.6K (-23.2%) | 0.53% -0.190 pp | 0.00% 0.000 pp | USD16.17 -6.2% | 30 qtrs — |
| 25 | TUDOR INVESTMENT CORP ET AL | 202.6K -14.4K (-6.7%) | 3.07M -106.0K (-3.3%) | 0.51% -0.040 pp | 0.01% +0.000 pp | USD14.54 +4.3% | 9 qtrs — |
| 26 | RUSSELL INVESTMENTS GROUP, LTD. | 197.9K +8.2K (+4.3%) | 3.00M +222.9K (+8.0%) | 0.50% +0.017 pp | 0.00% +0.000 pp | USD16.76 -9.5% | 29 qtrs — |
| 27 | GAMCO INVESTORS, INC. ET AL | 171.8K +— (+0.0%) | 2.60M +89.3K (+3.6%) | 0.43% -0.003 pp | 0.03% +0.001 pp | USD33.61 -54.9% | 30 qtrs — |
| 28 | GREAT LAKES ADVISORS, LLC | 154.9K -11.1K (-6.7%) | 2.35M -82.3K (-3.4%) | 0.39% -0.031 pp | 0.02% -0.001 pp | USD16.16 -6.2% | 12 qtrs — |
| 29 | JACOBS LEVY EQUITY MANAGEMENT, INC | 144.5K -855.0 (-0.6%) | 2.19M +62.6K (+2.9%) | 0.36% -0.005 pp | 0.01% +0.000 pp | USD12.37 +22.6% | 4 qtrs — |
| 30 | TREXQUANT INVESTMENT LP | 136.5K +93.4K (+216.8%) | 2.07M +1.4M (+228.0%) | 0.34% +0.234 pp | 0.02% +0.012 pp | USD15.00 +1.1% | 6 qtrs — |
| 31 | VOYA INVESTMENT MANAGEMENT LLC | 117.3K -22.9K (-16.4%) | 1.78M -274.8K (-13.4%) | 0.30% -0.060 pp | 0.00% 0.000 pp | USD13.80 +9.9% | 30 qtrs — |
| 32 | BANK OF NEW YORK MELLON CORP | 113.8K -2.4K (-2.1%) | 1.73M +24.3K (+1.4%) | 0.29% -0.008 pp | 0.00% +0.000 pp | USD35.55 -57.4% | 30 qtrs — |
| 33 | JANE STREET GROUP, LLC | 111.6K -98.4K (-46.9%) | 1.69M -1.4M (-45.0%) | 0.28% -0.251 pp | 0.00% 0.000 pp | USD14.83 +2.2% | 15 qtrs — |
| 34 | AMERICAN CENTURY COMPANIES INC | 101.9K -13.4K (-11.7%) | 1.54M -143.8K (-8.5%) | 0.26% -0.036 pp | 0.00% 0.000 pp | USD14.92 +1.6% | 11 qtrs — |
| 35 | BNP PARIBAS ARBITRAGE, SNC | 98.3K +11.2K (+12.9%) | 1.49M +215.4K (+16.9%) | 0.25% +0.027 pp | 0.00% +0.000 pp | USD14.77 +2.6% | 30 qtrs — |
| 36 | POINT72 ASSET MANAGEMENT, L.P. | 88.2K +88.2K (+100.0%) | 1.34M +1.3M (+100.0%) | 0.22% +0.222 pp | 0.00% +0.002 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 37 | AQR CAPITAL MANAGEMENT LLC | 86.7K +53.1K (+158.3%) | 1.31M +823.1K (+167.5%) | 0.22% +0.133 pp | 0.00% +0.000 pp | USD16.01 -5.3% | 30 qtrs — |
| 38 | BARCLAYS PLC | 85.2K -37.2K (-30.4%) | 1.29M -621.0K (-32.5%) | 0.21% -0.096 pp | 0.00% 0.000 pp | USD16.21 -6.5% | 30 qtrs — |
| 39 | ENGINEERS GATE MANAGER LP | 85.1K +40.9K (+92.6%) | 1.29M +643.4K (+99.5%) | 0.21% +0.102 pp | 0.02% +0.008 pp | USD15.07 +0.6% | 9 qtrs — |
| 40 | HIGHVISTA STRATEGIES LLC | 85.0K -8.2K (-8.7%) | 1.29M -75.1K (-5.5%) | 0.21% -0.022 pp | 0.33% -0.002 pp | USD15.17 -0.1% | 8 qtrs — |
| 41 | RENAISSANCE TECHNOLOGIES LLC | 81.4K -14.7K (-15.3%) | 1.23M -172.9K (-12.3%) | 0.20% -0.039 pp | 0.00% +0.000 pp | USD13.54 +12.0% | 30 qtrs — |
| 42 | FMR LLC | 81.3K +924.0 (+1.1%) | 1.23M +55.8K (+4.7%) | 0.20% +0.001 pp | 0.00% +0.000 pp | USD14.85 +2.1% | 16 qtrs — |
| 43 | DEUTSCHE BANK AG\ | 79.0K +1.5K (+1.9%) | 1.20M +62.6K (+5.5%) | 0.20% +0.002 pp | 0.00% +0.000 pp | USD18.95 -20.0% | 30 qtrs — |
| 44 | QUEST PARTNERS LLC | 73.1K +30.3K (+70.6%) | 1.11M +481.0K (+76.7%) | 0.18% +0.075 pp | 0.06% +0.021 pp | USD15.05 +0.7% | 7 qtrs — |
| 45 | UBS GROUP AG | 73.0K -38.4K (-34.5%) | 1.11M -524.2K (-32.2%) | 0.18% -0.098 pp | 0.00% 0.000 pp | USD12.42 +22.1% | 30 qtrs — |
| 46 | INVESCO LTD. | 72.0K -2.0K (-2.7%) | 1.09M +7.7K (+0.7%) | 0.18% -0.006 pp | 0.00% +0.000 pp | USD23.74 -36.1% | 30 qtrs — |
| 47 | VICTORY CAPITAL MANAGEMENT INC | 63.9K +700.0 (+1.1%) | 968.3K +43.5K (+4.7%) | 0.16% +0.001 pp | 0.00% +0.000 pp | USD13.12 +15.5% | 7 qtrs — |
| 48 | PRICE T ROWE ASSOCIATES INC /MD/ | 63.2K +16.6K (+35.5%) | 959.0K +275.0K (+40.2%) | 0.16% +0.041 pp | 0.00% +0.000 pp | USD15.83 -4.2% | 12 qtrs — |
| 49 | PANAGORA ASSET MANAGEMENT INC | 61.2K +13.1K (+27.2%) | 927.7K +223.4K (+31.7%) | 0.15% +0.032 pp | 0.00% +0.000 pp | USD15.72 -3.6% | 4 qtrs — |
| 50 | RHUMBLINE ADVISERS | 57.0K -9.9K (-14.8%) | 863.4K -115.4K (-11.8%) | 0.14% -0.026 pp | 0.00% 0.000 pp | USD29.02 -47.8% | 31 qtrs — |
| 51 | ALLIANCEBERNSTEIN L.P. | 45.5K +— (+0.0%) | 690.5K +23.7K (+3.6%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD27.06 -44.0% | 30 qtrs — |
| 52 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 45.3K -16.2K (-26.4%) | 687.2K -214.2K (-23.8%) | 0.11% -0.042 pp | 0.01% -0.004 pp | USD14.64 +3.6% | 2 qtrs — |
| 53 | WELLS FARGO & COMPANY/MN | 43.7K +13.8K (+45.9%) | 662.9K +224.1K (+51.1%) | 0.11% +0.034 pp | 0.00% +0.000 pp | USD15.81 -4.1% | 30 qtrs — |
| 54 | PALUMBO WEALTH MANAGEMENT LLC | 42.9K -44.0 (-0.1%) | 650.5K +21.7K (+3.4%) | 0.11% -0.001 pp | 0.16% -0.040 pp | USD14.64 +3.6% | 2 qtrs — |
| 55 | AMUNDI | 41.5K +1.1K (+2.7%) | 629.5K +56.5K (+9.9%) | 0.10% +0.002 pp | 0.00% +0.000 pp | USD14.65 +3.5% | 2 qtrs — |
| 56 | KIRR MARBACH & CO LLC /IN/ | 39.5K +— (+0.0%) | 598.2K +20.5K (+3.6%) | 0.10% -0.001 pp | 0.11% +0.010 pp | USD17.20 -11.9% | 5 qtrs — |
| 57 | TURTLE CREEK WEALTH ADVISORS, LLC | 35.1K +— (+0.0%) | 532.6K +18.3K (+3.6%) | 0.09% -0.001 pp | 0.04% -0.004 pp | USD13.48 +12.5% | 9 qtrs — |
| 58 | BOSTON PARTNERS | 30.9K -3.8K (-11.0%) | 467.8K -39.6K (-7.8%) | 0.08% -0.010 pp | 0.00% +0.000 pp | USD14.39 +5.4% | 12 qtrs — |
| 59 | INSPIRE INVESTING, LLC | 30.8K -538.0 (-1.7%) | 466.2K +8.1K (+1.8%) | 0.08% -0.002 pp | 0.04% -0.003 pp | USD13.80 +9.9% | 6 qtrs — |
| 60 | RBF CAPITAL, LLC | 30.0K +— (+0.0%) | 454.8K +15.6K (+3.6%) | 0.08% -0.001 pp | 0.02% +0.001 pp | USD12.88 +17.7% | 7 qtrs — |
| 61 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 27.4K +27.4K (+100.0%) | 415.9K +415.9K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.005 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 62 | Y-INTERCEPT (HONG KONG) LTD | 26.5K +26.5K (+100.0%) | 402.3K +402.3K (+100.0%) | 0.07% +0.067 pp | 0.01% +0.009 pp | USD15.16 +0.0% | 3 qtrs — |
| 63 | MAGNETAR FINANCIAL LLC | 25.8K +25.8K (+100.0%) | 391.0K +391.0K (+100.0%) | 0.06% +0.065 pp | 0.00% +0.004 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 64 | VERSOR INVESTMENTS LP | 24.1K -10.6K (-30.5%) | 365.4K -142.7K (-28.1%) | 0.06% -0.027 pp | 0.06% -0.037 pp | USD14.92 +1.6% | 5 qtrs — |
| 65 | TEJARA CAPITAL LTD | 21.8K +— (+0.0%) | 330.8K +11.3K (+3.6%) | 0.05% 0.000 pp | 0.08% -0.089 pp | USD15.55 -2.5% | 10 qtrs — |
| 66 | ASSENAGON ASSET MANAGEMENT S.A. | 21.3K -8.1K (-27.6%) | 323.1K -107.8K (-25.0%) | 0.05% -0.021 pp | 0.00% 0.000 pp | USD16.18 -6.3% | 6 qtrs — |
| 67 | METLIFE INVESTMENT MANAGEMENT, LLC | 21.2K -1.4K (-6.2%) | 322.1K -9.6K (-2.9%) | 0.05% -0.004 pp | 0.00% +0.000 pp | USD28.09 -46.0% | 30 qtrs — |
| 68 | CITIGROUP INC | 20.4K -20.2K (-49.7%) | 309.7K -284.8K (-47.9%) | 0.05% -0.051 pp | 0.00% 0.000 pp | USD15.86 -4.4% | 30 qtrs — |
| 69 | CITADEL ADVISORS LLC | 19.5K +19.5K (+100.0%) | 296.3K +296.3K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD15.16 +0.0% | 30 qtrs — |
| 70 | INTECH INVESTMENT MANAGEMENT LLC | 19.2K +590.0 (+3.2%) | 291.1K +18.6K (+6.8%) | 0.05% +0.001 pp | 0.00% +0.000 pp | USD17.14 -11.6% | 5 qtrs — |
| 71 | WALLEYE CAPITAL LLC | 18.1K +18.1K (+100.0%) | 274.9K +274.9K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.001 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 72 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 18.0K -143.0 (-0.8%) | 273.1K +7.3K (+2.7%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD13.28 +14.2% | 7 qtrs — |
| 73 | QUANTINNO CAPITAL MANAGEMENT LP | 17.9K +2.3K (+14.8%) | 271.1K +43.0K (+18.9%) | 0.05% +0.006 pp | 0.00% 0.000 pp | USD14.71 +3.1% | 2 qtrs — |
| 74 | GSA CAPITAL PARTNERS LLP | 17.1K +17.1K (+100.0%) | 260.0K +260.0K (+100.0%) | 0.04% +0.043 pp | 0.02% +0.022 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 75 | BALYASNY ASSET MANAGEMENT L.P. | 15.7K +15.7K (+100.0%) | 238.4K +238.4K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 76 | GRADIENT CAPITAL ADVISORS, LLC | 15.0K -5.0K (-25.0%) | 227.4K -65.4K (-22.3%) | 0.04% -0.013 pp | 0.06% -0.020 pp | USD11.15 +36.0% | 3 qtrs — |
| 77 | NATIONAL BANK OF CANADA /FI/ | 15.0K +15.0K (+100.0%) | 227.3K +227.3K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 78 | STATE OF WYOMING | 13.3K -1.5K (-10.2%) | 201.0K -15.2K (-7.0%) | 0.03% -0.004 pp | 0.02% -0.003 pp | USD13.85 +9.5% | 9 qtrs — |
| 79 | SQUAREPOINT OPS LLC | 12.9K -72.3K (-84.9%) | 195.7K -1.1M (-84.3%) | 0.03% -0.183 pp | 0.00% -0.001 pp | USD11.99 +26.4% | 4 qtrs — |
| 80 | CREATIVE PLANNING | 12.7K +961.0 (+8.2%) | 192.9K +20.7K (+12.0%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD14.68 +3.3% | 2 qtrs — |
| 81 | R SQUARED LTD | 12.6K +12.6K (+100.0%) | 191.2K +191.2K (+100.0%) | 0.03% +0.032 pp | 0.09% +0.089 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 12.6K -1.1K (-8.0%) | 191.2K -9.4K (-4.7%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD15.77 -3.9% | 12 qtrs — |
| 83 | FOX RUN MANAGEMENT, L.L.C. | 12.1K +12.1K (+100.0%) | 183.2K +183.2K (+100.0%) | 0.03% +0.030 pp | 0.03% +0.028 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 84 | PRUDENTIAL FINANCIAL INC | 11.0K -5.9K (-34.9%) | 166.8K -80.7K (-32.6%) | 0.03% -0.015 pp | 0.00% 0.000 pp | USD11.15 +36.0% | 3 qtrs — |
| 85 | AQUATIC CAPITAL MANAGEMENT LLC | 11.0K -1.5K (-12.1%) | 166.5K -16.3K (-8.9%) | 0.03% -0.004 pp | 0.00% +0.001 pp | USD12.19 +24.4% | 17 qtrs — |
| 86 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 10.7K +— (+0.0%) | 161.6K +5.5K (+3.6%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD16.57 -8.5% | 5 qtrs — |
| 87 | D. E. SHAW & CO., INC. | 10.6K -6.9K (-39.7%) | 159.9K -96.0K (-37.5%) | 0.03% -0.018 pp | 0.00% 0.000 pp | USD13.11 +15.6% | 7 qtrs — |
| 88 | DIVERSIFIED TRUST CO | 10.5K +10.5K (+100.0%) | 158.9K +158.9K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.003 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 89 | MACKENZIE FINANCIAL CORP | 10.3K +192.0 (+1.9%) | 158.1K +9.6K (+6.5%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD14.65 +3.5% | 2 qtrs — |
| 90 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 10.1K +— (+0.0%) | 152.7K +5.2K (+3.6%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD13.17 +15.1% | 30 qtrs — |
| 91 | QUANTBOT TECHNOLOGIES LP | 9.4K +9.4K (+100.0%) | 142.0K +142.0K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.005 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 92 | STRS OHIO | 9.2K +— (+0.0%) | 139.5K +4.8K (+3.6%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD16.31 -7.1% | 4 qtrs — |
| 93 | NEW YORK STATE COMMON RETIREMENT FUND | 8.2K +— (+0.0%) | 124.0K +4.3K (+3.6%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD40.89 -62.9% | 30 qtrs — |
| 94 | CANADA PENSION PLAN INVESTMENT BOARD | 6.0K +6.0K (+100.0%) | 91.0K +91.0K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.000 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 95 | SIMPLEX TRADING, LLC | 5.1K -359.0 (-6.5%) | 78.0K -2.0K (-2.5%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD14.25 +6.4% | 3 qtrs — |
| 96 | CWM, LLC | 4.5K +2.6K (+136.4%) | 69.0K +41.0K (+146.4%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD14.47 +4.8% | 6 qtrs — |
| 97 | HIGHMARK WEALTH MANAGEMENT LLC | 4.4K +— (+0.0%) | 66.8K +2.3K (+3.6%) | 0.01% 0.000 pp | 0.03% -0.001 pp | USD16.81 -9.8% | 12 qtrs — |
| 98 | KESTRA ADVISORY SERVICES, LLC | 3.7K +3.7K (+100.0%) | 55.6K +55.6K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD15.16 +0.0% | 1 qtrs NEW |
| 99 | LEGAL & GENERAL GROUP PLC | 3.5K +— (+0.0%) | 53.6K +1.8K (+3.6%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD31.11 -51.3% | 30 qtrs — |
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.63% | 137.6K | 0.20% |
| 2 | State Street SPDR S&P Health Care Equipment ETF XHE | 0.54% | 820.0K | 0.35% |
| 3 | Inspire Small/Mid Cap ETF ISMD | 0.26% | 845.0K | 0.53% |
| 4 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.15% | 135.3K | 0.89% |
| 5 | iShares Micro-Cap ETF IWC | 0.11% | 1.57M | 0.60% |
| 6 | State Street SPDR US Small Cap Low Volatility Index ETF SMLV | 0.09% | 220.8K | 0.12% |
| 7 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.07% | 771.6K | 0.20% |
| 8 | iShares U.S. Medical Devices ETF IHI | 0.07% | 2.20M | 0.38% |
| 9 | Texas Capital Texas Equity Index ETF TXS | 0.05% | 18.5K | 0.49% |
| 10 | Vanguard Global Value Factor ETF VVL.TO | 0.05% | 298.4K | 0.38% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Cedron Jorge Andres | Officer | S-Sale | D | Common Stock | 3,743 | 12.82 | 48.0K | 59,006 | D | ↗ |
| 2026-03-17 | Vitale Lucas | Officer | S-Sale | D | Common Stock | 4,269 | 11.92 | 50.9K | 160,449 | D | ↗ |
| 2026-03-10 | CAPPS VICKIE L | Director | P-Purchase | A | Common Stock | 2,400 | 12.45 | 29.9K | 27,585 | D | ↗ |
| 2026-03-09 | CAPPS VICKIE L | Director | P-Purchase | A | Common Stock | 2,500 | 12.48 | 31.2K | 25,085 | D | ↗ |
| 2026-03-05 | Vitale Lucas | Officer | S-Sale | D | Common Stock | 1,141 | 12.55 | 14.3K | 164,718 | D | ↗ |
| 2026-03-05 | REINHARDT MAX | Officer | S-Sale | D | Common Stock | 1,053 | 12.55 | 13.2K | 25,348 | D | ↗ |
| 2026-03-05 | McPherron Aviva | Officer | S-Sale | D | Common Stock | 1,263 | 12.55 | 15.9K | 67,853 | D | ↗ |
| 2026-03-05 | Fisher Patrick | Officer | S-Sale | D | Common Stock | 758 | 12.55 | 9.5K | 50,633 | D | ↗ |
| 2026-03-05 | Cedron Jorge Andres | Officer | S-Sale | D | Common Stock | 1,370 | 12.55 | 17.2K | 62,749 | D | ↗ |
| 2026-03-05 | Calafiore Massimo | Director / Officer | S-Sale | D | Common Stock | 6,031 | 12.55 | 75.7K | 320,136 | D | ↗ |
| 2026-03-05 | Andrews Julie | Officer | S-Sale | D | Common Stock | 2,363 | 12.55 | 29.7K | 88,746 | D | ↗ |
| 2026-03-04 | Vitale Lucas | Officer | S-Sale | D | Common Stock | 1,171 | 12.92 | 15.1K | 165,859 | D | ↗ |
| 2026-03-04 | REINHARDT MAX | Officer | S-Sale | D | Common Stock | 1,080 | 12.92 | 13.9K | 26,401 | D | ↗ |
| 2026-03-04 | McPherron Aviva | Officer | S-Sale | D | Common Stock | 1,296 | 12.92 | 16.7K | 69,116 | D | ↗ |
| 2026-03-04 | Fisher Patrick | Officer | S-Sale | D | Common Stock | 778 | 12.92 | 10.0K | 51,391 | D | ↗ |
| 2026-03-04 | Cedron Jorge Andres | Officer | S-Sale | D | Common Stock | 1,405 | 12.92 | 18.1K | 64,119 | D | ↗ |
| 2026-03-04 | Calafiore Massimo | Director / Officer | S-Sale | D | Common Stock | 6,189 | 12.92 | 79.9K | 326,167 | D | ↗ |
| 2026-03-04 | Andrews Julie | Officer | S-Sale | D | Common Stock | 2,425 | 12.92 | 31.3K | 91,109 | D | ↗ |
| 2026-03-03 | Vitale Lucas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 45,546 | 13.03 | 593.5K | 45,546 | D | ↗ |
| 2026-03-03 | McPherron Aviva | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 54,656 | 13.03 | 712.2K | 54,656 | D | ↗ |
| 2026-03-03 | Fisher Patrick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,101 | 13.03 | 652.8K | 50,101 | D | ↗ |
| 2026-03-03 | Cedron Jorge Andres | Officer | A-Award | A | Common Stock | 23,024 | 0.00 | — | 65,524 | D | ↗ |
| 2026-03-03 | Calafiore Massimo | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 273,279 | 13.03 | 3.56M | 273,279 | D | ↗ |
| 2026-03-03 | Andrews Julie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 84,261 | 13.03 | 1.10M | 84,261 | D | ↗ |
| 2026-02-25 | Engine Capital Management, LP | 10% Owner | P-Purchase | A | Common Stock | 9,959 | 12.96 | 129.1K | 3,673,092 | I | ↗ |
| 2026-02-24 | Engine Capital Management, LP | 10% Owner | P-Purchase | A | Common Stock | 7,721 | 12.55 | 96.9K | 369,933 | I | ↗ |
| 2026-01-16 | Andrews Julie | Officer | S-Sale | D | Common Stock | 4,873 | 14.38 | 70.1K | 58,039 | D | ↗ |
| 2026-01-12 | Calafiore Massimo | Director / Officer | S-Sale | D | Common Stock | 9,797 | 15.21 | 149.0K | 217,237 | D | ↗ |
| 2026-01-09 | Calafiore Massimo | Director / Officer | S-Sale | D | Common Stock | 9,600 | 15.82 | 151.9K | 227,034 | D | ↗ |
| 2025-08-18 | Fisher Patrick | Officer | S-Sale | D | Common Stock | 1,996 | 14.21 | 28.4K | 30,116 | D | ↗ |
| 2025-07-02 | Engine Capital Management, LP | 10% Owner | P-Purchase | A | Common Stock | 1,250 | 11.11 | 13.9K | 3,546,057 | I | ↗ |
| 2025-06-18 | Paolucci Michael E | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 86,948 | D | ↗ |
| 2025-06-18 | McPherron Aviva | Officer | S-Sale | D | Common Stock | 3,728 | 10.51 | 39.2K | 46,322 | D | ↗ |
| 2025-06-18 | Maniar Shweta | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 54,073 | D | ↗ |
| 2025-06-18 | Kummeth Charles R. | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 59,237 | D | ↗ |
| 2025-06-18 | Hannon Jason | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 70,594 | D | ↗ |
| 2025-06-18 | HENNEMAN JOHN B III | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 83,706 | D | ↗ |
| 2025-06-18 | Finegan Michael | Director | A-Award | A | Common Stock | 26,087 | 0.00 | — | 57,391 | D | ↗ |
| 2025-06-18 | CAPPS VICKIE L | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 21,934 | D | ↗ |
| 2025-06-18 | Bazaar Alan Lee | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 49,824 | D | ↗ |
| 2025-06-18 | BURRIS WAYNE | Director | A-Award | A | Common Stock | 18,841 | 0.00 | — | 50,539 | D | ↗ |
| 2025-06-11 | REINHARDT MAX | Officer | S-Sale | D | Common Stock | 1,643 | 11.64 | 19.1K | 27,481 | D | ↗ |
| 2025-06-04 | Bazaar Alan Lee | Director | P-Purchase | A | Common Stock | 2,250 | 10.92 | 24.6K | 30,983 | D | ↗ |
| 2025-05-12 | Bazaar Alan Lee | Director | P-Purchase | A | Common Stock | 2,000 | 12.59 | 25.2K | 28,733 | D | ↗ |
| 2025-05-09 | Calafiore Massimo | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 12.54 | 125.4K | 234,603 | D | ↗ |
| 2025-05-09 | Bazaar Alan Lee | Director | P-Purchase | A | Common Stock | 1,990 | 12.62 | 25.1K | 26,733 | D | ↗ |
| 2025-05-07 | Engine Capital Management, LP | 10% Owner | P-Purchase | A | Common Stock | 83,375 | 12.31 | 1.03M | 3,544,807 | I | ↗ |
| 2025-05-06 | Engine Capital Management, LP | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 3,461,432 | I | ↗ |
| 2025-05-01 | McPherron Aviva | Officer | — | — | Common Stock | 0 | 0.00 | — | 50,050 | D | ↗ |
| 2025-04-16 | Cedron Jorge Andres | Officer | S-Sale | D | Common Stock | 3,816 | 13.31 | 50.8K | 42,500 | D | ↗ |
| 2025-04-02 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 76 | 15.74 | 1.2K | 42,445 | D | ↗ |
| 2025-03-18 | Vitale Lucas | Officer | S-Sale | D | Common Stock | 4,287 | 16.60 | 71.2K | 135,317 | D | ↗ |
| 2025-03-18 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 296 | 16.60 | 4.9K | 42,521 | D | ↗ |
| 2025-03-11 | CAPPS VICKIE L | Director | A-Award | A | Employee Stock Option (Right to Buy) | 35,270 | 17.10 | 603.1K | 35,270 | D | ↗ |
| 2025-03-03 | Vitale Lucas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 34,924 | 16.98 | 593.0K | 34,924 | D | ↗ |
| 2025-03-03 | REINHARDT MAX | Officer | A-Award | A | Common Stock | 14,723 | 0.00 | — | 29,124 | D | ↗ |
| 2025-03-03 | Gillespie Geoffrey C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 8,731 | 16.98 | 148.3K | 8,731 | D | ↗ |
| 2025-03-03 | Fisher Patrick | Officer | A-Award | A | Common Stock | 14,723 | 0.00 | — | 30,042 | D | ↗ |
| 2025-03-03 | Cedron Jorge Andres | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 41,908 | 16.98 | 711.6K | 41,908 | D | ↗ |
| 2025-03-03 | Calafiore Massimo | Director / Officer | A-Award | A | Common Stock | 88,339 | 0.00 | — | 212,490 | D | ↗ |
| 2025-03-03 | Andrews Julie | Officer | A-Award | A | Common Stock | 34,600 | 0.00 | — | 62,912 | D | ↗ |
| 2025-02-04 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 187 | 18.08 | 3.4K | 39,136 | D | ↗ |
| 2025-02-03 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 767 | 17.79 | 13.6K | 39,323 | D | ↗ |
| 2025-01-16 | Andrews Julie | Officer | S-Sale | D | Common Stock | 4,655 | 17.89 | 83.3K | 28,312 | D | ↗ |
| 2025-01-13 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 227 | 17.14 | 3.9K | 40,090 | D | ↗ |
| 2025-01-13 | Calafiore Massimo | Director / Officer | S-Sale | D | Common Stock | 9,203 | 17.14 | 157.8K | 124,151 | D | ↗ |
| 2025-01-10 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 248 | 16.83 | 4.2K | 40,317 | D | ↗ |
| 2025-01-10 | Calafiore Massimo | Director / Officer | S-Sale | D | Common Stock | 10,078 | 16.83 | 169.6K | 133,354 | D | ↗ |
| 2025-01-08 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 238 | 16.97 | 4.0K | 40,565 | D | ↗ |
| 2025-01-07 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 238 | 17.14 | 4.1K | 40,803 | D | ↗ |
| 2024-12-17 | Gillespie Geoffrey C | Officer | S-Sale | D | Common Stock | 26 | 17.84 | 463.84 | 41,041 | D | ↗ |
| 2024-08-15 | Fisher Patrick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 35,195 | 16.32 | 574.4K | 35,195 | — | ↗ |
| 2024-06-18 | Vitale Lucas | Officer | — | D | Employee Stock Option (Right to Buy) | 75,432 | 13.74 | 1.04M | 0 | — | ↗ |
| 2024-06-18 | Paolucci Michael E | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 66,766 | — | ↗ |
| 2024-06-18 | Maniar Shweta | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 35,232 | — | ↗ |
| 2024-06-18 | Kummeth Charles R. | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 38,502 | — | ↗ |
| 2024-06-18 | Hannon Jason | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 49,364 | — | ↗ |
| 2024-06-18 | HENNEMAN JOHN B III | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 63,914 | — | ↗ |
| 2024-06-18 | Finegan Michael | Director | A-Award | A | Common Stock | 21,368 | 12.87 | 275.0K | 29,718 | — | ↗ |
| 2024-06-18 | Bazaar Alan Lee | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 24,088 | — | ↗ |
| 2024-06-18 | BURRIS WAYNE | Director | A-Award | A | Common Stock | 15,152 | 12.87 | 195.0K | 31,698 | — | ↗ |
| 2024-06-10 | REINHARDT MAX | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 190,731 | 13.02 | 2.48M | 190,731 | — | ↗ |
| 2024-06-08 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 4,267 | 13.42 | 57.3K | 227,747 | — | ↗ |
| 2024-04-15 | Cedron Jorge Andres | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 64,817 | 13.09 | 848.5K | 64,817 | — | ↗ |
| 2024-04-11 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 2,938 | 13.95 | 41.0K | 232,014 | — | ↗ |
| 2024-04-08 | BURZIK CATHERINE M | Director | F-InKind | D | Common Stock | 47,486 | 14.23 | 675.7K | 112,803 | — | ↗ |
| 2024-04-01 | Gillespie Geoffrey C | Officer | F-InKind | D | Common Stock | 70 | 14.06 | 984.20 | 40,772 | — | ↗ |
| 2024-04-01 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 2,031 | 14.06 | 28.6K | 234,952 | — | ↗ |
| 2024-03-15 | Gillespie Geoffrey C | Officer | A-Award | A | Common Stock | 3,639 | 13.74 | 50.0K | 40,842 | — | ↗ |
| 2024-02-01 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 2,015 | 14.27 | 28.8K | 236,983 | — | ↗ |
| 2024-01-31 | Kummeth Charles R. | Director | A-Award | A | Common Stock | 8,350 | 13.89 | 116.0K | 23,350 | — | ↗ |
| 2024-01-31 | Finegan Michael | Director | A-Award | A | Common Stock | 8,350 | 13.89 | 116.0K | 8,350 | — | ↗ |
| 2024-01-31 | Bazaar Alan Lee | Director | A-Award | A | Common Stock | 8,936 | 13.89 | 124.1K | 8,936 | — | ↗ |
| 2024-01-15 | Andrews Julie | Officer | A-Award | A | Common Stock | 32,967 | 13.65 | 450.0K | 32,967 | — | ↗ |
| 2024-01-08 | Kenny Kevin J. | Officer | M-Exempt | D | Performance Share Units | 5,959 | 0.00 | — | 0 | — | ↗ |
| 2024-01-08 | Gillespie Geoffrey C | Officer | A-Award | A | Common Stock | 4,703 | 13.29 | 62.5K | 37,385 | — | ↗ |
| 2024-01-08 | Elting Kimberley A. | Officer | A-Award | D | Common Stock | 18,811 | 13.29 | 250.0K | 238,998 | — | ↗ |
| 2024-01-08 | Calafiore Massimo | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2024-01-05 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 2,955 | 12.67 | 37.4K | 141,362 | — | ↗ |
| 2024-01-05 | Gillespie Geoffrey C | Officer | F-InKind | D | Common Stock | 459 | 12.67 | 5.8K | 32,682 | — | ↗ |
| 2024-01-05 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 5,228 | 12.67 | 66.2K | 220,187 | — | ↗ |
| 2024-01-03 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 1,778 | 12.96 | 23.0K | 225,415 | — | ↗ |
| 2023-12-18 | Kummeth Charles R. | Director | A-Award | A | Stock Option (right to buy) | 47,652 | 13.06 | 622.3K | 47,652 | — | ↗ |
| 2023-12-18 | Finegan Michael | Director | A-Award | A | Stock Option (right to buy) | 47,652 | 13.06 | 622.3K | 47,652 | — | ↗ |
| 2023-12-18 | Bazaar Alan Lee | Director | A-Award | A | Stock Option (right to buy) | 47,652 | 13.06 | 622.3K | 47,652 | — | ↗ |
| 2023-12-18 | BURRIS WAYNE | Director | A-Award | A | Stock Option (right to buy) | 47,652 | 13.06 | 622.3K | 47,652 | — | ↗ |
| 2023-12-15 | Gillespie Geoffrey C | Officer | F-InKind | D | Common Stock | 24 | 12.12 | 290.88 | 33,141 | — | ↗ |
| 2023-12-14 | Kummeth Charles R. | Director | — | D | Common Stock | 0 | 0.00 | — | 15,000 | — | ↗ |
| 2023-12-14 | Finegan Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-12 | Bazaar Alan Lee | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-04 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 609 | 10.79 | 6.6K | 144,317 | — | ↗ |
| 2023-11-17 | Elting Kimberley A. | Officer | A-Award | A | Common Stock | 47,664 | 0.00 | — | 227,193 | — | ↗ |
| 2023-10-15 | Leekha Puja | Officer | A-Award | A | Common Stock | 32,180 | 0.00 | — | 47,316 | — | ↗ |
| 2023-10-15 | Gillespie Geoffrey C | Officer | A-Award | A | Common Stock | 23,331 | 0.00 | — | 33,074 | — | ↗ |
| 2023-10-15 | BURZIK CATHERINE M | Director / Officer | A-Award | A | Common Stock | 120,676 | 0.00 | — | 158,625 | — | ↗ |
| 2023-09-14 | Hinrichs James F. | Director | P-Purchase | A | Common Stock | 7,500 | 13.47 | 101.0K | 86,153 | — | ↗ |
| 2023-09-12 | Leekha Puja | Officer | — | D | Common Stock | 0 | 0.00 | — | 15,136 | — | ↗ |
| 2023-09-12 | Gillespie Geoffrey C | Officer | — | D | Common Stock | 0 | 0.00 | — | 9,743 | — | ↗ |
| 2023-06-19 | BURZIK CATHERINE M | Director | A-Award | A | Common Stock | 3,589 | 0.00 | — | 37,949 | — | ↗ |
| 2023-06-19 | BURRIS WAYNE | Director | — | D | Common Stock | 0 | 0.00 | — | 6,383 | — | ↗ |
| 2023-05-26 | Kenny Kevin J. | Officer | S-Sale | D | Common Stock | 3,876 | 19.00 | 73.6K | 142,431 | — | ↗ |
| 2023-05-24 | Kenny Kevin J. | Officer | S-Sale | D | Common Stock | 4,367 | 19.00 | 83.0K | 146,307 | — | ↗ |
| 2023-04-11 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 1,469 | 17.77 | 26.1K | 148,087 | — | ↗ |
| 2023-04-11 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 2,938 | 17.77 | 52.2K | 177,841 | — | ↗ |
| 2023-04-04 | Kenny Kevin J. | Officer | A-Award | A | Common Stock | 7,449 | 0.00 | — | 148,724 | — | ↗ |
| 2023-04-03 | Serbousek Jon Carl | Director / Officer | F-InKind | D | Common Stock | 6,141 | 16.75 | 102.9K | 346,827 | — | ↗ |
| 2023-04-03 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 1,956 | 16.75 | 32.8K | 141,275 | — | ↗ |
| 2023-04-03 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 2,385 | 16.75 | 39.9K | 180,779 | — | ↗ |
| 2023-03-10 | Maniar Shweta | Director | S-Sale | D | Common Stock | 4,262 | 17.75 | 75.7K | 20,080 | — | ↗ |
| 2023-02-28 | Valentine Keith | Director / Officer | F-InKind | D | Common Stock | 16,290 | 20.60 | 335.6K | 377,741 | — | ↗ |
| 2023-02-28 | Keran Patrick L | Officer | F-InKind | D | Common Stock | 3,792 | 20.60 | 78.1K | 84,407 | — | ↗ |
| 2023-02-28 | Bostjancic John J. | Officer | F-InKind | D | Common Stock | 3,783 | 30.60 | 115.8K | 99,670 | — | ↗ |
| 2023-02-01 | Serbousek Jon Carl | Director / Officer | F-InKind | D | Common Stock | 5,142 | 21.54 | 110.8K | 352,968 | — | ↗ |
| 2023-02-01 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 2,287 | 21.54 | 49.3K | 143,231 | — | ↗ |
| 2023-02-01 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 2,015 | 21.54 | 43.4K | 183,164 | — | ↗ |
| 2023-01-30 | Valentine Keith | Director / Officer | F-InKind | D | Common Stock | 5,824 | 21.22 | 123.6K | 394,031 | — | ↗ |
| 2023-01-30 | Keran Patrick L | Officer | F-InKind | D | Common Stock | 999 | 21.22 | 21.2K | 88,199 | — | ↗ |
| 2023-01-30 | Bostjancic John J. | Officer | F-InKind | D | Common Stock | 1,694 | 21.22 | 35.9K | 103,453 | — | ↗ |
| 2023-01-08 | Elting Kimberley A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 43,867 | 13.29 | 583.0K | 43,867 | — | ↗ |
| 2023-01-05 | Valentine Keith | Officer | A-Award | A | Common Stock | 140,515 | 0.00 | — | 399,855 | — | ↗ |
| 2023-01-05 | Serbousek Jon Carl | Officer | A-Award | A | Common Stock | 45,872 | 0.00 | — | 235,379 | — | ↗ |
| 2023-01-05 | Paolucci Michael E | Director | A-Award | A | Common Stock | 14,052 | 0.00 | — | 48,687 | — | ↗ |
| 2023-01-05 | Maniar Shweta | Director | A-Award | A | Common Stock | 14,052 | 0.00 | — | 24,040 | — | ↗ |
| 2023-01-05 | Keran Patrick L | Officer | A-Award | A | Common Stock | 35,128 | 0.00 | — | 89,198 | — | ↗ |
| 2023-01-05 | Kenny Kevin J. | Officer | J-Other | A | Common Stock | 832 | 0.00 | — | 146,350 | — | ↗ |
| 2023-01-05 | Hinrichs James F. | Director | A-Award | A | Common Stock | 14,052 | 0.00 | — | 77,557 | — | ↗ |
| 2023-01-05 | Hannon Jason | Director | A-Award | A | Common Stock | 14,052 | 0.00 | — | 31,285 | — | ↗ |
| 2023-01-05 | HENNEMAN JOHN B III | Director | — | D | Stock Option (right to buy) | 5,794 | 24.00 | 139.1K | — | — | ↗ |
| 2023-01-05 | Elting Kimberley A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 84,566 | 0.00 | — | 84,566 | — | ↗ |
| 2023-01-05 | ESSIG STUART | Director | A-Award | A | Common Stock | 14,052 | 0.00 | — | 205,664 | — | ↗ |
| 2023-01-05 | Bostjancic John J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 84,566 | 0.00 | — | 84,566 | — | ↗ |
| 2023-01-05 | BURZIK CATHERINE M | Director | A-Award | A | Common Stock | 14,052 | 0.00 | — | 32,754 | — | ↗ |
| 2023-01-05 | BURRIS WAYNE | Director | — | D | Stock Option (right to buy) | 22,184 | 39.36 | 873.2K | 0 | — | ↗ |
| 2023-01-03 | Elting Kimberley A. | Officer | A-Award | A | Common Stock | 11,710 | 0.00 | — | 105,795 | — | ↗ |
| 2022-12-31 | MARKS LILLY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-05 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 984 | 20.02 | 19.7K | 72,407 | — | ↗ |
| 2022-11-01 | Serbousek Jon Carl | Officer | F-InKind | D | Common Stock | 2,369 | 16.21 | 38.4K | 186,551 | — | ↗ |
| 2022-09-05 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 365 | 19.53 | 7.1K | 94,085 | — | ↗ |
| 2022-08-05 | Serbousek Jon Carl | Officer | F-InKind | D | Common Stock | 1,450 | 22.77 | 33.0K | 188,920 | — | ↗ |
| 2022-06-06 | West Thomas A. | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 6,543 | — | ↗ |
| 2022-06-06 | SICARD JOHN | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 21,615 | — | ↗ |
| 2022-06-06 | Paolucci Michael E | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 33,903 | — | ↗ |
| 2022-06-06 | MARKS LILLY | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 37,520 | — | ↗ |
| 2022-06-06 | Hinrichs James F. | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 62,727 | — | ↗ |
| 2022-06-06 | Hannon Jason | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 16,501 | — | ↗ |
| 2022-06-06 | BURZIK CATHERINE M | Director | A-Award | A | Common Stock | 8,844 | 0.00 | — | 17,443 | — | ↗ |
| 2022-06-06 | BURRIS WAYNE | Director | A-Award | A | Common Stock | 6,383 | 0.00 | — | 6,383 | — | ↗ |
| 2022-04-11 | Kenny Kevin J. | Officer | A-Award | A | Common Stock | 14,937 | 0.00 | — | 69,625 | — | ↗ |
| 2022-04-11 | Elting Kimberley A. | Officer | A-Award | A | Common Stock | 29,874 | 0.00 | — | 94,450 | — | ↗ |
| 2022-04-11 | DOUG RICE | Officer | A-Award | A | Common Stock | 14,937 | 0.00 | — | 107,679 | — | ↗ |
| 2022-04-02 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 334 | 33.04 | 11.0K | 64,576 | — | ↗ |
| 2022-04-01 | Serbousek Jon Carl | Officer | F-InKind | D | Common Stock | 3,899 | 33.04 | 128.8K | 190,880 | — | ↗ |
| 2022-04-01 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 753 | 33.04 | 24.9K | 54,688 | — | ↗ |
| 2022-04-01 | Gonsalves Paul | Officer | F-InKind | D | Common Stock | 687 | 33.04 | 22.7K | 25,716 | — | ↗ |
| 2022-04-01 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 1,202 | 33.04 | 39.7K | 64,910 | — | ↗ |
| 2022-04-01 | DOUG RICE | Officer | F-InKind | D | Common Stock | 385 | 33.04 | 12.7K | 93,105 | — | ↗ |
| 2022-02-01 | Serbousek Jon Carl | Director / Officer | A-Award | A | Performance Share Units | 81,967 | 0.00 | — | 81,967 | — | ↗ |
| 2022-02-01 | Kenny Kevin J. | Officer | A-Award | A | Performance Share Units | 20,492 | 0.00 | — | 20,492 | — | ↗ |
| 2022-02-01 | Gonsalves Paul | Officer | A-Award | A | Performance Share Units | 9,836 | 0.00 | — | 9,836 | — | ↗ |
| 2022-02-01 | Elting Kimberley A. | Officer | A-Award | A | Performance Share Units | 20,492 | 0.00 | — | 20,492 | — | ↗ |
| 2022-02-01 | DOUG RICE | Officer | A-Award | A | Common Stock | 22,131 | 0.00 | — | 95,674 | — | ↗ |
| 2022-01-05 | Keran Patrick L | Officer | — | D | Employee Stock Option (Right to Buy) | 9,035 | 36.04 | 325.6K | — | — | ↗ |
| 2021-12-13 | West Thomas A. | Director | A-Award | A | Stock Option (right to buy) | 29,450 | 29.12 | 857.6K | 29,450 | — | ↗ |
| 2021-12-04 | Kenny Kevin J. | Officer | F-InKind | D | Common Stock | 984 | 30.24 | 29.8K | 36,151 | — | ↗ |
| 2021-11-22 | Paolucci Michael E | Director | P-Purchase | A | Common Stock | 2,000 | 31.15 | 62.3K | 27,141 | — | ↗ |
| 2021-11-19 | DOUG RICE | Officer | P-Purchase | A | Common Stock | 1,400 | 30.05 | 42.1K | 73,543 | — | ↗ |
| 2021-11-19 | BURZIK CATHERINE M | Director | P-Purchase | A | Common Stock | 1,660 | 30.27 | 50.2K | 7,947 | — | ↗ |
| 2021-11-18 | Serbousek Jon Carl | Director / Officer | P-Purchase | A | Common Stock | 1,670 | 31.14 | 52.0K | 112,812 | — | ↗ |
| 2021-11-18 | Elting Kimberley A. | Officer | P-Purchase | A | Common Stock | 1,000 | 30.34 | 30.3K | 46,803 | — | ↗ |
| 2021-11-01 | Serbousek Jon Carl | Director / Officer | F-InKind | D | Common Stock | 2,369 | 36.87 | 87.3K | 109,903 | — | ↗ |
| 2021-09-22 | BURRIS WAYNE | Director | A-Award | A | Stock Option (right to buy) | 22,184 | 39.36 | 873.2K | 22,184 | — | ↗ |
| 2021-09-11 | Gonsalves Paul | Officer | F-InKind | D | Common Stock | 1,045 | 40.59 | 42.4K | 16,567 | — | ↗ |
| 2021-09-05 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 365 | 42.69 | 15.6K | 44,953 | — | ↗ |
| 2021-08-05 | Serbousek Jon Carl | Director / Officer | F-InKind | D | Common Stock | 1,450 | 37.98 | 55.1K | 112,272 | — | ↗ |
| 2021-07-03 | Elting Kimberley A. | Officer | F-InKind | D | Common Stock | 346 | 40.48 | 14.0K | 45,318 | — | ↗ |
| 2021-07-03 | DOUG RICE | Officer | F-InKind | D | Common Stock | 373 | 40.48 | 15.1K | 70,370 | — | ↗ |
| 2021-06-21 | SICARD JOHN | Director | A-Award | A | Common Stock | 4,313 | 0.00 | — | 15,232 | — | ↗ |
| 2021-06-21 | Paolucci Michael E | Director | A-Award | A | Common Stock | 4,313 | 0.00 | — | 24,814 | — | ↗ |
| 2021-06-21 | MARKS LILLY | Director | A-Award | A | Common Stock | 4,313 | 0.00 | — | 30,573 | — | ↗ |
| 2021-06-21 | Lukianov Alexis V | Director | A-Award | A | Common Stock | 4,313 | 0.00 | — | 21,027 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Massimo Calafiore - President and Chief Executive Officer | 848.3K | — | 4.50M | 1.50M | 445.6K | 16.1K | 7.31M | 82.08% | ↗ |
| 2 | 2025 | Julie Andrews - Chief Financial Officer | 488.4K | — | 1.76M | 587.5K | 163.3K | 16.2K | 3.02M | 77.87% | ↗ |
| 3 | 2025 | J. Andrés Cedrón - Chief Legal Officer | 483.3K | — | 900.0K | 300.0K | 161.5K | 213.1K | 2.06M | 58.31% | ↗ |
| 4 | 2025 | Aviva McPherron - President, Global Operations and Quality | 447.3K | — | 900.0K | 300.0K | 149.5K | 15.1K | 1.81M | 66.23% | ↗ |
| 5 | 2025 | Patrick Fisher - President, Global Biologics and Limb Reconstruction | 462.7K | 150.0K | 750.0K | 250.0K | 154.7K | 29.5K | 1.80M | 55.65% | ↗ |
| 6 | 2024 | Massimo Calafiore - President and Chief Executive Officer | 793.3K | — | 6.56M | 2.01M | 926.6K | 337.9K | 10.63M | 80.64% | ↗ |
| 7 | 2024 | Lucas Vitale - Chief People and Business Operations Officer Former Officers: | 355.6K | — | 2.77M | 477.3K | 328.8K | 191.4K | 4.13M | 78.78% | ↗ |
| 8 | 2024 | Julie Andrews - Chief Financial Officer | 447.6K | — | 1.57M | 483.3K | 339.5K | 323.1K | 3.17M | 64.95% | ↗ |
| 9 | 2024 | Kimberley A. Elting - Former President, Global Orthopedics and Interim Chief Legal Officer | 305.3K | 220.6K | 1.66M | 580.4K | — | 19.4K | 2.78M | 80.41% | ↗ |
| 10 | 2024 | Max Reinhardt - President, Global Spine | 258.5K | — | 655.8K | 1.14M | 301.4K | 429.1K | 2.78M | 64.47% | ↗ |
| 11 | 2024 | J. Andrés Cedrón - Chief Legal Officer | 325.4K | — | 1.31M | 390.7K | 335.9K | 879.00 | 2.36M | 72.00% | ↗ |
| 12 | 2024 | Geoffrey C. Gillespie - Chief Accounting Officer and Former Interim Chief Financial Officer | 330.5K | 60.9K | 268.6K | 112.5K | 141.5K | 3.9K | 917.9K | 41.52% | ↗ |
| 13 | 2024 | Catherine Burzik - Former Interim Chief Executive Officer | 31.7K | — | — | — | — | 10.1K | 41.8K | 0.00% | ↗ |
| 14 | 2023 | Jon C. Serbousek - President and Chief Executive Officer | 424.6K | 428.1K | 10.61M | 836.9K | — | 3.33M | 15.63M | 73.22% | ↗ |
| 15 | 2023 | Keith C. Valentine - Former President and Chief Executive Officer | 598.7K | — | 2.94M | 2.94M | — | 12.3K | 6.48M | 90.58% | ↗ |
| 16 | 2023 | Douglas C. Rice - Former Chief Financial Officer | 9.1K | — | 3.31M | 236.7K | — | 408.2K | 3.97M | 89.48% | ↗ |
| 17 | 2023 | Kimberley A. Elting - Former President, Global Orthopedics and Interim Chief Legal Officer | 494.6K | 250.0K | 1.67M | 734.1K | 374.6K | 32.5K | 3.55M | 67.58% | ↗ |
| 18 | 2023 | Kimberley A. Elting - President, Global Orthopedics and Interim Chief Legal Officer | 494.6K | 250.0K | 1.67M | 734.1K | 374.6K | 32.5K | 3.55M | 67.58% | ↗ |
| 19 | 2023 | Kevin J. Kenny - Former President, Global Spine Former Officers: | 494.4K | 100.0K | 1.02M | 790.5K | 285.7K | 15.3K | 2.71M | 66.92% | ↗ |
| 20 | 2023 | Catherine Burzik - Former Interim Chief Executive Officer | 234.8K | 137.6K | 1.87M | — | 227.7K | 87.0K | 2.56M | 73.14% | ↗ |
| 21 | 2023 | John Bostjancic - Former Chief Financial Officer | 367.2K | — | 734.2K | 734.1K | — | 12.4K | 1.85M | 79.46% | ↗ |
| 22 | 2023 | Patrick L. Keran - Former Chief Legal Officer | 352.5K | — | 734.2K | 734.1K | — | 12.2K | 1.83M | 80.11% | ↗ |
| 23 | 2023 | Puja Leekha - Former Interim Chief Legal Officer | 121.5K | — | 700.0K | 300.0K | — | 14.9K | 1.14M | 88.00% | ↗ |
| 24 | 2023 | Geoffrey C. Gillespie - Chief Accounting Officer and Former Interim Chief Financial Officer | 263.6K | — | 387.3K | 97.3K | 94.6K | 44.3K | 887.0K | 54.63% | ↗ |
| 25 | 2023 | Geoffrey C. Gillespie - Corporate Controller and Former Interim Chief Financial Officer | 263.6K | — | 387.3K | 97.3K | 94.6K | 44.3K | 887.0K | 54.63% | ↗ |
| 26 | 2022 | Jon C. Serbousek - President and Chief Executive Officer | 800.0K | — | 5.00M | — | 446.0K | 70.0K | 6.32M | 79.16% | ↗ |
| 27 | 2022 | Kimberley A. Elting - Former President, Global Orthopedics and Interim Chief Legal Officer | 475.5K | — | 2.20M | — | 270.7K | 20.4K | 2.97M | 74.16% | ↗ |
| 28 | 2022 | Kimberley A. Elting - President, Global Orthopedics and Chief Legal and Development Officer | 475.5K | — | 2.20M | — | 270.7K | 20.4K | 2.97M | 74.16% | ↗ |
| 29 | 2022 | Kimberley A. Elting - President, Global Orthopedics and Interim Chief Legal Officer | 475.5K | — | 2.20M | — | 270.7K | 20.4K | 2.97M | 74.16% | ↗ |
| 30 | 2022 | Douglas C. Rice - Former Chief Financial Officer | 475.5K | — | 1.82M | — | 176.8K | 14.1K | 2.49M | 73.25% | ↗ |
| 31 | 2022 | Douglas C. Rice - Chief Financial Officer | 475.5K | — | 1.82M | — | 176.8K | 14.1K | 2.49M | 73.25% | ↗ |
| 32 | 2022 | Kevin J. Kenny - President, Global Spine | 475.6K | — | 1.73M | — | 118.5K | 13.6K | 2.33M | 73.95% | ↗ |
| 33 | 2022 | Kevin J. Kenny - Former President, Global Spine Former Officers: | 475.6K | — | 1.73M | — | 118.5K | 13.6K | 2.33M | 73.95% | ↗ |
| 34 | 2022 | Paul W. Gonsalves - Former President, Global Orthopedics | 127.5K | — | 600.0K | — | — | 14.0K | 741.4K | 80.93% | ↗ |
| 35 | 2021 | Jon C. Serbousek - President and Chief Executive Officer | 775.0K | — | 3.73M | — | 720.8K | 116.8K | 5.34M | 69.81% | ↗ |
| 36 | 2021 | Douglas C. Rice - Chief Financial Officer | 461.3K | — | 1.23M | — | 300.3K | 21.0K | 2.01M | 61.02% | ↗ |
| 37 | 2021 | Douglas C. Rice - Former Chief Financial Officer | 461.3K | — | 1.23M | — | 300.3K | 21.0K | 2.01M | 61.02% | ↗ |
| 38 | 2021 | Kimberley A. Elting - President, Global Orthopedics and Interim Chief Legal Officer | 461.3K | — | 1.12M | — | 300.3K | 19.6K | 1.90M | 58.88% | ↗ |
| 39 | 2021 | Kimberley A. Elting - Chief and Development Officer | 461.3K | — | 1.12M | — | 300.3K | 19.6K | 1.90M | 58.88% | ↗ |
| 40 | 2021 | Kimberley A. Elting - President, Global Orthopedics and Chief Legal and Development Officer | 461.3K | — | 1.12M | — | 300.3K | 19.6K | 1.90M | 58.88% | ↗ |
| 41 | 2021 | Kevin J. Kenny - President of Global Spine | 461.3K | — | 1.12M | — | 298.3K | 19.4K | 1.90M | 58.95% | ↗ |
| 42 | 2021 | Kevin J. Kenny - Former President, Global Spine Former Officers: | 461.3K | — | 1.12M | — | 298.3K | 19.4K | 1.90M | 58.95% | ↗ |
| 43 | 2021 | Kevin J. Kenny - President, Global Spine | 461.3K | — | 1.12M | — | 298.3K | 19.4K | 1.90M | 58.95% | ↗ |
| 44 | 2021 | Paul W. Gonsalves - President of Global Orthopedics | 402.5K | — | 639.1K | — | 268.1K | 50.6K | 1.36M | 46.98% | ↗ |
| 45 | 2021 | Paul W. Gonsalves - Former President, Global Orthopedics | 402.5K | — | 639.1K | — | 268.1K | 50.6K | 1.36M | 46.98% | ↗ |
| 46 | 2020 | Jon C. Serbousek - President and Chief Executive Officer | 726.9K | — | 2.89M | 875.0K | 750.0K | 92.6K | 5.34M | 70.60% | ↗ |
| 47 | 2020 | Douglas C. Rice - Chief Financial Officer | 432.1K | — | 760.6K | 230.0K | 315.0K | 17.3K | 1.76M | 56.44% | ↗ |
| 48 | 2020 | Kevin J. Kenny - President, Global Spine | 426.5K | 100.0K | 661.3K | 200.0K | 308.0K | 47.7K | 1.74M | 49.40% | ↗ |
| 49 | 2020 | Kevin J. Kenny - President of Global Spine | 426.5K | 100.0K | 661.3K | 200.0K | 308.0K | 47.7K | 1.74M | 49.40% | ↗ |
| 50 | 2020 | Kimberley A. Elting - President, Global Orthopedics and Chief Legal and Development Officer | 430.7K | — | 727.5K | 220.0K | 315.0K | 15.9K | 1.71M | 55.44% | ↗ |
| 51 | 2020 | Kimberley A. Elting - Chief and Development Officer | 430.7K | — | 727.5K | 220.0K | 315.0K | 15.9K | 1.71M | 55.44% | ↗ |
| 52 | 2020 | Davide Bianchi - Former President of Global Extremities | 310.1K | — | — | — | 216.3K | 869.7K | 1.40M | 0.00% | ↗ |
| 53 | 2020 | Paul W. Gonsalves - President of Global Orthopedics | 116.9K | — | 300.0K | 300.0K | 85.9K | 106.8K | 909.7K | 65.96% | ↗ |
| 54 | 2020 | Paul W. Gonsalves - President of Global Extremities | 116.9K | — | 300.0K | 300.0K | 85.9K | 106.8K | 909.7K | 65.96% | ↗ |
| 55 | 2019 | Jon C. Serbousek - President and Chief Executive Officer | 241.3K | 304.1K | 1.75M | 1.75M | — | 30.9K | 4.08M | 85.86% | ↗ |
| 56 | 2019 | Bradley R. Mason - Former President and Chief Executive Officer | 623.3K | — | 2.00M | — | 165.9K | 95.8K | 2.88M | 69.33% | ↗ |
| 57 | 2019 | Douglas C. Rice - Chief Financial Officer | 432.6K | — | 1.16M | 220.0K | 70.1K | 12.5K | 1.90M | 72.87% | ↗ |
| 58 | 2019 | Kimberley A. Elting - Chief and Development Officer | 426.4K | — | 1.10M | 202.5K | 69.1K | 12.6K | 1.81M | 71.93% | ↗ |
| 59 | 2019 | Kimberley A. Elting - Chief Legal and Administrative Officer | 426.4K | — | 1.10M | 202.5K | 69.1K | 12.6K | 1.81M | 71.93% | ↗ |
| 60 | 2019 | Michael M. Finegan - Chief Strategy Officer | 424.3K | — | 1.05M | 187.5K | 68.7K | 13.3K | 1.74M | 70.92% | ↗ |
| 61 | 2019 | Davide Bianchi - Former President of Global Extremities | 414.6K | — | 995.5K | 175.0K | 23.3K | 89.4K | 1.70M | 68.94% | ↗ |
| 62 | 2019 | Davide Bianchi - President of Global Extremities | 414.6K | — | 995.5K | 175.0K | 23.3K | 89.4K | 1.70M | 68.94% | ↗ |
| 63 | 2018 | Bradley R. Mason - President and Chief Executive Officer | 740.0K | — | 3.59M | 1.05M | 488.4K | 16.7K | 5.89M | 78.87% | ↗ |
| 64 | 2018 | Bradley R. Mason - Former President and Chief Executive Officer | 740.0K | — | 3.59M | 1.05M | 488.4K | 16.7K | 5.89M | 78.87% | ↗ |
| 65 | 2018 | Kimberley A. Elting - Chief and Development Officer | 410.0K | — | 859.7K | 193.6K | 162.4K | 12.3K | 1.64M | 64.31% | ↗ |
| 66 | 2018 | Kimberley A. Elting - Chief Legal and Administrative Officer | 410.0K | — | 859.7K | 193.6K | 162.4K | 12.3K | 1.64M | 64.31% | ↗ |
| 67 | 2018 | Douglas C. Rice - Chief Financial Officer | 420.0K | — | 715.0K | 209.9K | 166.3K | 12.3K | 1.52M | 60.71% | ↗ |
| 68 | 2018 | Bradley V. Niemann - President of Global Spine | 391.0K | — | 659.4K | 143.7K | 195.9K | 941.00 | 1.39M | 57.74% | ↗ |
| 69 | 2018 | Michael M. Finegan - Chief Strategy Officer | 418.0K | — | 553.3K | 162.4K | 165.5K | 13.1K | 1.31M | 54.53% | ↗ |
| 70 | 2018 | Davide Bianchi - President of Global Extremities | 398.6K | — | 489.4K | 143.7K | 150.6K | 81.8K | 1.26M | 50.09% | ↗ |
| 71 | 2018 | Davide Bianchi - Former President of Global Extremities | 398.6K | — | 489.4K | 143.7K | 150.6K | 81.8K | 1.26M | 50.09% | ↗ |
| 72 | 2017 | Bradley R. Mason - President and Chief Executive Officer | 710.8K | — | 2.35M | 706.0K | 920.5K | 13.7K | 4.71M | 65.04% | ↗ |
| 73 | 2017 | Bradley R. Mason - Former President and Chief Executive Officer | 710.8K | — | 2.35M | 706.0K | 920.5K | 13.7K | 4.71M | 65.04% | ↗ |
| 74 | 2017 | Douglas C. Rice - Chief Financial Officer | 390.0K | — | 588.7K | 176.5K | 303.0K | 11.9K | 1.47M | 52.05% | ↗ |
| 75 | 2017 | Kimberley A. Elting - Chief Legal and Administrative Officer | 382.0K | — | 546.7K | 163.9K | 296.8K | 10.9K | 1.40M | 50.75% | ↗ |
| 76 | 2017 | Michael M. Finegan - Chief Strategy Officer | 412.0K | — | 504.6K | 151.3K | 320.1K | 11.9K | 1.40M | 46.85% | ↗ |
| 77 | 2017 | Davide Bianchi - President of Global Extremities | 365.0K | — | 462.5K | 138.7K | 281.9K | 69.3K | 1.32M | 45.64% | ↗ |
| 78 | 2017 | Bradley V. Niemann - President of Global Spine | 370.0K | — | 462.5K | 138.7K | 258.6K | 884.00 | 1.23M | 48.85% | ↗ |
| 79 | 2016 | Bradley R. Mason - President and Chief Executive Officer | 705.6K | — | 2.58M | 762.1K | 763.0K | 19.2K | 4.83M | 69.22% | ↗ |
| 80 | 2016 | Bradley V. Niemann - President, BioStim | 345.5K | — | 824.1K | 139.8K | 263.2K | 6.3K | 1.58M | 61.05% | ↗ |
| 81 | 2016 | Bradley V. Niemann - President of Global Spine | 345.5K | — | 824.1K | 139.8K | 263.2K | 6.3K | 1.58M | 61.05% | ↗ |
| 82 | 2016 | Michael M. Finegan - Chief Strategy Officer | 402.0K | — | 516.1K | 152.2K | 259.3K | 19.0K | 1.35M | 49.56% | ↗ |
| 83 | 2016 | Doug Rice - Chief Financial Officer | 350.5K | — | 560.6K | 165.3K | 225.6K | 17.2K | 1.32M | 55.02% | ↗ |
| 84 | 2016 | Douglas C. Rice - Chief Financial Officer | 350.5K | — | 560.6K | 165.3K | 225.6K | 17.2K | 1.32M | 55.02% | ↗ |
| 85 | 2016 | Davide Bianchi - President, Global Extremity Fixation | 357.5K | — | 474.1K | 139.8K | 249.0K | 71.1K | 1.29M | 47.54% | ↗ |
| 86 | 2016 | Jeffrey M. Schumm - Former Chief Administrative Officer, General Counsel, and Corporate Secretary | 238.8K | — | — | — | 155.3K | 656.8K | 1.05M | 0.00% | ↗ |
| 87 | 2015 | Bradley R. Mason - President and Chief Executive Officer since March 13, 2013 | 689.2K | — | 1.66M | 473.7K | 710.7K | 26.8K | 3.56M | 59.92% | ↗ |
| 88 | 2015 | Bradley R. Mason - President and Chief Executive Officer | 689.2K | — | 1.66M | 473.7K | 710.7K | 26.8K | 3.56M | 59.92% | ↗ |
| 89 | 2015 | Jeffrey M. Schumm - Chief Administrative Officer, General Counsel, and Corporate Secretary | 408.2K | — | 941.6K | 146.1K | 208.7K | 26.3K | 1.73M | 62.84% | ↗ |
| 90 | 2015 | Jeffrey M. Schumm - Former Chief Administrative Officer, General Counsel, and Corporate Secretary | 408.2K | — | 941.6K | 146.1K | 208.7K | 26.3K | 1.73M | 62.84% | ↗ |
| 91 | 2015 | Doug Rice - Chief Financial Officer | 337.5K | — | 795.2K | 226.4K | 172.4K | 22.5K | 1.55M | 65.74% | ↗ |
| 92 | 2015 | Michael M. Finegan - Chief Strategy Officer | 403.4K | — | 402.4K | 114.9K | 206.2K | 24.4K | 1.15M | 44.93% | ↗ |
| 93 | 2015 | Davide Bianchi - President, Global Extremity Fixation since July 2013 | 359.5K | — | 402.4K | 114.9K | 147.4K | 73.6K | 1.10M | 47.12% | ↗ |
| 94 | 2015 | Davide Bianchi - President, Global Extremity Fixation | 359.5K | — | 402.4K | 114.9K | 147.4K | 73.6K | 1.10M | 47.12% | ↗ |
| 95 | 2014 | Bradley R. Mason - President and Chief Executive Officer | 610.8K | — | 1.71M | 486.3K | 612.2K | 26.1K | 3.45M | 63.80% | ↗ |
| 96 | 2014 | Bradley R. Mason – President and Chief Executive Officer since March 13, 2013 | 610.8K | — | 1.71M | 486.3K | 612.2K | 26.1K | 3.45M | 63.80% | ↗ |
| 97 | 2014 | Bradley R. Mason - President and Chief Executive Officer since March 13, 2013 | 610.8K | — | 1.71M | 486.3K | 612.2K | 26.1K | 3.45M | 63.80% | ↗ |
| 98 | 2014 | Mark Heggestad, Former Chief Financial Officer | 169.9K | — | 1.48M | 454.1K | — | 9.6K | 2.11M | 91.49% | ↗ |
| 99 | 2014 | Jeffrey M. Schumm – Chief Administrative Officer, General Counsel and Corporate Secretary | 381.8K | 250.0K | 560.1K | 176.4K | 183.5K | 22.5K | 1.57M | 46.78% | ↗ |
| 100 | 2014 | Jeffrey M. Schumm - Former Chief Administrative Officer, General Counsel, and Corporate Secretary | 381.8K | 225.0K | 560.1K | 176.4K | 183.5K | 22.5K | 1.55M | 47.53% | ↗ |
| 101 | 2014 | Jeffrey M. Schumm - Chief Administrative Officer, General Counsel, and Corporate Secretary | 381.8K | 225.0K | 560.1K | 176.4K | 183.5K | 22.5K | 1.55M | 47.53% | ↗ |
| 102 | 2014 | Michael M. Finegan – Chief Strategy Officer | 380.9K | 250.0K | 402.4K | 126.7K | 183.1K | 24.2K | 1.37M | 38.70% | ↗ |
| 103 | 2014 | Michael M. Finegan - Chief Strategy Officer | 380.9K | 225.0K | 402.4K | 126.7K | 183.1K | 24.2K | 1.34M | 39.42% | ↗ |
| 104 | 2014 | Davide Bianchi - President, Global Extremity Fixation since July 2013 | 365.9K | 189.4K | 402.4K | 126.7K | 175.8K | 74.3K | 1.33M | 39.65% | ↗ |
| 105 | 2014 | Davide Bianchi – President, Global Extremity Fixation since July 2013 | 365.9K | 189.4K | 402.4K | 126.7K | 175.8K | 74.3K | 1.33M | 39.65% | ↗ |
| 106 | 2014 | Davide Bianchi - President, Global Extremity Fixation | 365.9K | 189.4K | 402.4K | 126.7K | 175.8K | 74.3K | 1.33M | 39.65% | ↗ |
| 107 | 2014 | Doug Rice, Chief Financial Officer | 91.3K | 47.0K | 265.6K | 99.5K | 16.1K | 5.6K | 525.2K | 69.52% | ↗ |
| 108 | 2014 | Doug Rice - Chief Financial Officer | 91.3K | 47.0K | 265.6K | 99.5K | 16.1K | 5.6K | 525.2K | 69.52% | ↗ |
| 109 | 2014 | Emily Buxton – Former Chief Financial Officer | 139.6K | 97.5K | — | — | — | 13.8K | 250.9K | 0.00% | ↗ |
| 110 | 2014 | David Ziegler, Former Interim Chief Financial Officer | 17.1K | 90.5K | — | — | — | 85.2K | 192.8K | 0.00% | ↗ |
| 111 | 2013 | Robert S. Vaters – President and Chief Executive Officer until March 13, 2013 | 245.0K | — | — | — | — | 2.77M | 3.01M | 0.00% | ↗ |
| 112 | 2013 | Bradley R. Mason – President and Chief Executive Officer since March 13, 2013 | 452.8K | — | 388.2K | 2.15M | — | 21.9K | 3.01M | 84.24% | ↗ |
| 113 | 2013 | Bradley R. Mason - President and Chief Executive Officer since March 13, 2013 | 452.8K | — | 388.2K | 2.15M | — | 21.9K | 3.01M | 84.24% | ↗ |
| 114 | 2013 | Emily Buxton – Chief Financial Officer during 2013 | 317.2K | 50.0K | 497.8K | 437.4K | — | 21.7K | 1.32M | 70.63% | ↗ |
| 115 | 2013 | Michael M. Finegan – Chief Strategy Officer | 360.0K | 100.0K | 408.4K | 152.8K | — | 22.2K | 1.04M | 53.78% | ↗ |
| 116 | 2013 | Michael M. Finegan - Chief Strategy Officer | 360.0K | 100.0K | 408.4K | 152.8K | — | 22.2K | 1.04M | 53.78% | ↗ |
| 117 | 2013 | Jeffrey M. Schumm - Chief Administrative Officer, General Counsel, and Corporate Secretary | 355.0K | 100.0K | 408.4K | 152.8K | — | 22.3K | 1.04M | 54.04% | ↗ |
| 118 | 2013 | Jeffrey M. Schumm – Chief Administrative Officer, General Counsel and Corporate Secretary | 355.0K | 100.0K | 408.4K | 152.8K | — | 22.3K | 1.04M | 54.04% | ↗ |
| 119 | 2013 | Davide Bianchi – President, Global Extremity Fixation since July 2013 | 364.2K | 73.0K | 218.2K | 169.4K | — | 68.0K | 892.8K | 43.42% | ↗ |
| 120 | 2013 | Davide Bianchi - President, Global Extremity Fixation since July 2013 | 364.2K | 73.0K | 218.2K | 169.4K | — | 68.0K | 892.8K | 43.42% | ↗ |
| 121 | 2012 | Robert S. Vaters – President and Chief Executive Officer until March 13, 2013 | 667.9K | 175.0K | 1.64M | 1.61M | 86.6K | 74.9K | 4.25M | 76.38% | ↗ |
| 122 | 2012 | Robert S. Vaters – former President and Chief Executive Officer prior to March 13, 2013 (Principal Executive Officer during 2012 fiscal year) | 667.9K | 175.0K | 1.64M | 1.61M | 86.6K | 74.9K | 4.25M | 76.38% | ↗ |
| 123 | 2012 | Brian McCollum – President, Global Spine Business Unit (Principal Financial Officer between January 1, 2012 and November 10, 2012) | 346.2K | 175.0K | 717.7K | 892.1K | 27.2K | 21.4K | 2.18M | 73.86% | ↗ |
| 124 | 2012 | Vicente Trelles – Executive Vice President of Worldwide Operations and Shared Services | 409.1K | 50.0K | 615.2K | 600.1K | 32.0K | 138.3K | 1.84M | 65.88% | ↗ |
| 125 | 2012 | Jeffrey M. Schumm – Chief Administrative Officer, General Counsel and Corporate Secretary | 322.1K | 75.0K | 553.6K | 683.9K | 25.2K | 36.7K | 1.70M | 72.94% | ↗ |
| 126 | 2012 | Jeffrey M. Schumm – Senior Vice President, General Counsel and Corporate Secretary | 322.1K | 75.0K | 553.6K | 683.9K | 25.2K | 36.7K | 1.70M | 72.94% | ↗ |
| 127 | 2012 | Michael M. Finegan – Chief Strategy Officer | 342.7K | 75.0K | 615.2K | 600.1K | 26.8K | 19.7K | 1.68M | 72.36% | ↗ |
| 128 | 2012 | Michael M. Finegan – Senior Vice President, Corporate Development and President, Biologics | 342.7K | 75.0K | 615.2K | 600.1K | 26.8K | 19.7K | 1.68M | 72.36% | ↗ |
| 129 | 2012 | Emily Buxton – Chief Financial Officer during 2013 | 272.7K | — | — | 128.4K | 11.3K | 21.3K | 433.8K | 29.61% | ↗ |
| 130 | 2012 | Emily Buxton – Chief Financial Officer (Principal Financial Officer since November 11, 2012) | 272.7K | — | — | 128.4K | 11.3K | 21.3K | 433.8K | 29.61% | ↗ |
| 131 | 2011 | Vicente Trelles — Executive Vice President of Worldwide Operations and Shared Services | 264.5K | 50.0K | — | 2.12M | 162.0K | 9.5K | 2.61M | 81.35% | ↗ |
| 132 | 2011 | Vicente Trelles – Executive Vice President of Worldwide Operations and Shared Services | 264.5K | 50.0K | — | 2.12M | 162.0K | 9.5K | 2.61M | 81.35% | ↗ |
| 133 | 2011 | Robert S. Vaters —President and Chief Executive Officer effective August 1, 2011 (Principal Executive Officer since 8/1/11 and Principal Financial Officer prior to 1/10/11) | 512.7K | 290.0K | 496.9K | 678.8K | 395.5K | 74.8K | 2.45M | 48.01% | ↗ |
| 134 | 2011 | Robert S. Vaters – President and Chief Executive Officer until March 13, 2013 | 512.7K | 290.0K | 496.9K | 678.8K | 395.5K | 74.8K | 2.45M | 48.01% | ↗ |
| 135 | 2011 | Robert S. Vaters – former President and Chief Executive Officer prior to March 13, 2013 (Principal Executive Officer during 2012 fiscal year) | 512.7K | 290.0K | 496.9K | 678.8K | 395.5K | 74.8K | 2.45M | 48.01% | ↗ |
| 136 | 2011 | Alan W. Milinazzo — former President and Chief Executive Officer prior to August 1, 2011 (Principal Executive Officer prior to 8/1/11) | 359.1K | — | 584.6K | 314.8K | 206.4K | 17.3K | 1.48M | 60.68% | ↗ |
| 137 | 2011 | Luigi Ferrari — President, Global Orthopedics Business Unit | 346.6K | 75.0K | 233.8K | 138.5K | 254.7K | 95.5K | 1.14M | 32.56% | ↗ |
| 138 | 2011 | Bryan McMillan — President, Global Spine Business Unit | 387.1K | 120.0K | — | 366.0K | 157.5K | 11.5K | 1.04M | 35.12% | ↗ |
| 139 | 2011 | Michael M. Finegan – Senior Vice President, Corporate Development and President, Biologics | 328.7K | 75.0K | 292.3K | 163.7K | 132.8K | 19.2K | 1.01M | 45.07% | ↗ |
| 140 | 2011 | Michael M. Finegan – Chief Strategy Officer | 328.7K | 75.0K | 292.3K | 163.7K | 132.8K | 19.2K | 1.01M | 45.07% | ↗ |
| 141 | 2011 | Brian McCollum — Senior Vice President of Finance and Chief Financial Officer (Principal Financial Officer since 1/10/11) | 298.1K | 75.0K | 233.8K | 138.5K | 145.4K | 21.2K | 911.9K | 40.83% | ↗ |
| 142 | 2011 | Brian McCollum – President, Global Spine Business Unit (Principal Financial Officer between January 1, 2012 and November 10, 2012) | 298.1K | 75.0K | 233.8K | 138.5K | 145.4K | 21.2K | 911.9K | 40.83% | ↗ |
| 143 | 2010 | Alan W. Milinazzo — former President and Chief Executive Officer prior to August 1, 2011 (Principal Executive Officer prior to 8/1/11) | 545.6K | — | — | — | 530.7K | 23.2K | 1.10M | 0.00% | ↗ |
| 144 | 2010 | Alan W. Milinazzo – President and Chief Executive Officer through July 31, 2011 (Principal Executive Officer during 2010) | 545.6K | — | — | — | 530.7K | 23.2K | 1.10M | 0.00% | ↗ |
| 145 | 2010 | Robert S. Vaters —President and Chief Executive Officer effective August 1, 2011 (Principal Executive Officer since 8/1/11 and Principal Financial Officer prior to 1/10/11) | 408.5K | — | — | — | 311.2K | 61.9K | 781.5K | 0.00% | ↗ |
| 146 | 2010 | Robert S. Vaters – Executive Vice President and Chief Operating Officer through July 31, 2011, and President and Chief Executive Officer effective August 1, 2011 (Principal Financial Officer during 2010) | 408.5K | — | — | — | 311.2K | 61.9K | 781.5K | 0.00% | ↗ |
| 147 | 2010 | Robert S. Vaters – former President and Chief Executive Officer prior to March 13, 2013 (Principal Executive Officer during 2012 fiscal year) | 408.5K | — | — | — | 311.2K | 61.9K | 781.5K | 0.00% | ↗ |
| 148 | 2010 | Kevin Unger – former President, Orthofix Spinal Implants | 267.7K | — | — | — | — | 263.7K | 531.4K | 0.00% | ↗ |
| 149 | 2010 | Raymond Kolls – former Senior Vice President, General Counsel and Corporate Secretary | 81.4K | — | — | — | — | 446.0K | 527.4K | 0.00% | ↗ |
| 150 | 2010 | Michael M. Finegan – Vice President, Corporate Development and President, Biologics | 318.9K | — | — | — | 172.4K | 24.1K | 515.4K | 0.00% | ↗ |
| 151 | 2010 | Luigi Ferrari – President, Global Orthopedics Business Unit | 298.1K | — | — | — | 175.6K | 40.3K | 514.0K | 0.00% | ↗ |
| 152 | 2010 | Luigi Ferrari — President, Global Orthopedics Business Unit | 298.1K | — | — | — | 175.6K | 40.3K | 514.0K | 0.00% | ↗ |
| 153 | 2010 | Michael M. Finegan – Senior Vice President, Corporate Development and President, Biologics | 318.9K | — | — | — | 172.4K | 21.5K | 512.8K | 0.00% | ↗ |
| 154 | 2010 | Eric Brown – former President, Spine Stimulation | 307.9K | — | — | — | 180.0K | 23.3K | 511.2K | 0.00% | ↗ |
| 155 | 2009 | Alan W. Milinazzo – President and Chief Executive Officer through July 31, 2011 (Principal Executive Officer during 2010) | 509.8K | — | — | 882.1K | 416.9K | 26.2K | 1.84M | 48.07% | ↗ |
| 156 | 2009 | Alan W. Milinazzo — former President and Chief Executive Officer prior to August 1, 2011 (Principal Executive Officer prior to 8/1/11) | 509.8K | — | — | 882.1K | 416.9K | 26.2K | 1.84M | 48.07% | ↗ |
| 157 | 2009 | Alan W. Milinazzo – President and Chief Executive Officer (Principal Executive Officer) | 509.8K | — | — | 882.1K | 416.9K | 26.2K | 1.84M | 48.07% | ↗ |
| 158 | 2009 | Robert S. Vaters – Executive Vice President and Chief Operating Officer through July 31, 2011, and President and Chief Executive Officer effective August 1, 2011 (Principal Financial Officer during 2010) | 363.8K | 100.0K | — | 905.4K | 238.1K | 74.4K | 1.68M | 53.84% | ↗ |
| 159 | 2009 | Robert S. Vaters —President and Chief Executive Officer effective August 1, 2011 (Principal Executive Officer since 8/1/11 and Principal Financial Officer prior to 1/10/11) | 363.8K | 100.0K | — | 905.4K | 238.1K | 74.4K | 1.68M | 53.84% | ↗ |
| 160 | 2009 | Robert S. Vaters – Executive Vice President and Chief Financial Officer (Principal Financial Officer) | 363.8K | 100.0K | — | 905.4K | 238.1K | 74.4K | 1.68M | 53.84% | ↗ |
| 161 | 2009 | Bradley R. Mason – Strategic Advisor | 373.5K | — | — | 735.1K | 290.5K | 33.1K | 1.43M | 51.33% | ↗ |
| 162 | 2009 | Michael M. Finegan – Vice President, Corporate Development and President, Biologics | 309.7K | — | — | 566.8K | 179.8K | 21.5K | 1.08M | 52.59% | ↗ |
| 163 | 2009 | Michael M. Finegan – President, Biologics and Vice President, Corporate Development | 309.7K | — | — | 566.8K | 179.8K | 21.5K | 1.08M | 52.59% | ↗ |
| 164 | 2009 | Eric Brown – President, Spine Stimulation | 299.1K | 3.8K | — | 337.2K | 219.9K | 23.6K | 883.6K | 38.16% | ↗ |
| 165 | 2009 | Eric Brown – former President, Spine Stimulation | 299.1K | 3.8K | — | 337.2K | 219.9K | 23.6K | 883.6K | 38.16% | ↗ |
| 166 | 2009 | Michael Simpson – President, Orthopedics North America | 289.9K | — | — | 241.5K | 207.4K | 20.3K | 759.0K | 31.82% | ↗ |
| 167 | 2009 | Luigi Ferrari – President, Global Orthopedics Business Unit | 303.5K | — | — | 241.5K | 163.9K | 45.8K | 754.7K | 32.00% | ↗ |
| 168 | 2009 | Kevin Unger – former President, Orthofix Spinal Implants | 106.4K | — | — | 538.3K | 66.3K | 6.9K | 717.9K | 74.98% | ↗ |
| 169 | 2009 | Raymond Kolls – former Senior Vice President, General Counsel and Corporate Secretary | 289.9K | — | — | 120.0K | 158.1K | 21.4K | 589.3K | 20.36% | ↗ |
| 170 | 2008 | Oliver Burckhardt – former President, Spine Division | 249.6K | — | — | 1.44M | — | 480.9K | 2.17M | 66.31% | ↗ |
| 171 | 2008 | Alan W. Milinazzo – President and Chief Executive Officer (Principal Executive Officer) | 500.0K | — | — | 1.06M | 148.5K | 21.1K | 1.73M | 61.36% | ↗ |
| 172 | 2008 | Thomas Hein – former Principal Financial Officer | 330.4K | 150.0K | — | 420.9K | 65.9K | 429.7K | 1.40M | 30.13% | ↗ |
| 173 | 2008 | Robert S. Vaters – Executive Vice President and Chief Financial Officer (Principal Financial Officer) | 107.7K | — | — | 996.2K | 69.3K | 24.6K | 1.20M | 83.17% | ↗ |
| 174 | 2008 | Alan W. Milinazzo – President and Chief Executive Officer (Principal Executive Officer) | 500.0K | — | — | 517.2K | 148.5K | 21.1K | 1.19M | 43.58% | ↗ |
| 175 | 2008 | Bradley R. Mason – Strategic Advisor | 322.1K | — | — | 624.2K | 197.2K | 35.6K | 1.18M | 52.93% | ↗ |
| 176 | 2008 | Bradley R. Mason – Group President, North America and President, Blackstone Medical, Inc. | 322.1K | — | — | 372.3K | 197.2K | 16.6K | 908.2K | 40.99% | ↗ |
| 177 | 2008 | Michael Simpson – President, Orthopedics North America | 280.0K | 105.0K | — | 290.6K | 165.2K | 20.4K | 861.2K | 33.75% | ↗ |
| 178 | 2008 | Michael Simpson – President, Orthopedics North America | 280.0K | 105.0K | — | 278.5K | 165.2K | 20.4K | 849.0K | 32.80% | ↗ |
| 179 | 2008 | Michael M. Finegan – Vice President, Corporate Development, and President, Biologics | 280.0K | — | — | 337.1K | 55.4K | 20.4K | 692.9K | 48.65% | ↗ |
| 180 | 2008 | Eric Brown – President, Spine Stimulation | 285.0K | 10.0K | — | 164.5K | 162.5K | 23.0K | 644.9K | 25.51% | ↗ |
| 181 | 2008 | Michael M. Finegan – President, Biologics and Vice President, Corporate Development | 280.0K | — | — | 277.8K | 55.4K | 20.4K | 633.6K | 43.84% | ↗ |
| 182 | 2008 | Robert S. Vaters – Executive Vice President and Chief Financial Officer (Principal Financial Officer) | 107.7K | — | — | 181.8K | 69.3K | 24.6K | 383.4K | 47.43% | ↗ |
| 183 | 2008 | Timothy M. Adams – former Principal Financial Officer | 131.9K | — | — | — | — | 3.8K | 135.7K | 0.00% | ↗ |
| 184 | 2007 | Alan W. Milinazzo – Executive Officer (Principal Executive Officer) | 451.5K | — | — | 1.15M | 54.6K | 243.8K | 1.68M | 68.35% | ↗ |
| 185 | 2007 | Alan W. Milinazzo – President and Chief Executive Officer (Principal Executive Officer) | 451.5K | — | — | 1.15M | 54.6K | 22.8K | 1.67M | 68.42% | ↗ |
| 186 | 2007 | Thomas Hein – former Principal Financial Officer | 281.2K | — | — | 1.06M | 24.3K | 24.8K | 1.39M | 76.31% | ↗ |
| 187 | 2007 | Thomas Hein – Chief and Assistant Secretary (Principal Financial Officer) | 281.2K | — | — | 1.06M | 24.3K | 24.6K | 1.39M | 76.32% | ↗ |
| 188 | 2007 | Bradley R. Mason – Group President, North America and President, Blackstone Medical, Inc. | 282.2K | — | — | 839.4K | 172.1K | 13.5K | 1.31M | 64.21% | ↗ |
| 189 | 2007 | Bradley R. Mason – Company and President, Breg, Inc. | 283.3K | — | — | 839.4K | 172.1K | 12.2K | 1.31M | 64.23% | ↗ |
| 190 | 2007 | Oliver Burckhardt – former President, Spine Division | 263.5K | 94.2K | — | 383.2K | 51.1K | 20.1K | 812.1K | 47.19% | ↗ |
| 191 | 2007 | Oliver Burckhardt – former President, Spine Division | 263.5K | 75.0K | — | 383.2K | 51.1K | 19.4K | 792.2K | 48.38% | ↗ |
| 192 | 2007 | Michael M. Finegan – Vice President, Corporate Development, and President, Biologics | 257.3K | — | — | 381.6K | 30.0K | 20.1K | 689.0K | 55.39% | ↗ |
| 193 | 2007 | Michael M. Finegan – Corporate Development | 257.3K | — | — | 381.6K | 30.0K | 19.9K | 688.8K | 55.41% | ↗ |
| 194 | 2007 | Michael Simpson – President, Orthopedics North America | 240.0K | — | — | — | 94.3K | 15.2K | 620.2K | 0.00% | ↗ |
| 195 | 2007 | Timothy M. Adams – former Principal Financial Officer | 40.4K | — | — | 159.2K | — | 1.3K | 200.8K | 79.27% | ↗ |
| 196 | 2007 | Timothy M. Adams – (former Principal Financial Officer) | 40.4K | — | — | 159.2K | — | — | 199.6K | 79.76% | ↗ |
| 197 | 2007 | Robert S. Vaters – Executive Vice President and Chief Financial Officer (Principal Financial Officer) | — | — | — | — | — | — | — | — | ↗ |
| 198 | 2006 | Alan W. Milinazzo – President and Chief Executive Officer (Principal Executive Officer) | 407.5K | 40.0K | — | 905.0K | 178.5K | 34.5K | 1.57M | 57.81% | ↗ |
| 199 | 2006 | Alan W. Milinazzo – Executive Officer (Principal Executive Officer) | 407.5K | 40.0K | — | 905.0K | 178.5K | 34.5K | 1.57M | 57.81% | ↗ |
| 200 | 2006 | Charles W. Federico – Former President and Chief Executive Officer (Principal Executive Officer) | 156.4K | — | — | 656.0K | 49.9K | 569.3K | 1.43M | 45.82% | ↗ |
| 201 | 2006 | Bradley R. Mason – Company and President, Breg, Inc. | 257.5K | — | — | 618.5K | 24.7K | 11.8K | 912.5K | 67.78% | ↗ |
| 202 | 2006 | Bradley R. Mason – Vice President of the Company and President, Breg, Inc. | 257.5K | — | — | 618.5K | 24.7K | 11.8K | 912.5K | 67.78% | ↗ |
| 203 | 2006 | Thomas Hein – Chief Financial Officer (Principal Financial Officer) | 270.4K | 25.0K | — | 294.2K | 90.2K | 30.2K | 710.0K | 41.43% | ↗ |
| 204 | 2006 | Thomas Hein – Chief and Assistant Secretary (Principal Financial Officer) | 270.4K | 25.0K | — | 294.2K | 90.2K | 30.2K | 710.0K | 41.43% | ↗ |
| 205 | 2006 | Raymond C. Kolls – Senior Vice President, General Counsel and Corporate Secretary | 220.6K | 25.0K | — | 249.7K | 66.8K | 28.5K | 590.7K | 42.28% | ↗ |
| 206 | 2006 | Galvin Mould – Former Vice President and President, International Division | 44.2K | — | — | 59.7K | — | 455.3K | 559.2K | 10.68% | ↗ |
| 207 | 2006 | Michael M. Finegan – Vice President of Corporate Development | 139.5K | 100.0K | — | 196.5K | 85.8K | — | 521.7K | 37.67% | ↗ |
| 208 | 2006 | Michael M. Finegan – Corporate Development | 139.5K | 100.0K | — | 196.5K | 85.8K | — | 521.7K | 37.67% | ↗ |
| 209 | 2006 | Oliver Burckhardt – former President, Spine Division | 40.5K | 35.2K | — | — | — | — | 114.4K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Massimo Calafiore | President, Chief Executive Officer & Director | 1M | male |
| Max Reinhardt | President of the Global Spine Business | 1M | male |
| Lucas S. Vitale | Chief People & Business Operations Officer | 875.8K | male |
| J. Andres Cedron | Chief Legal Officer & Corporate Secretary | 858.0K | male |
| Julie Andrews | Chief Financial Officer | 667.8K | female |
| Geoffrey C. Gillespie | Chief Accounting Officer | 536.8K | male |
| Stephanie Walsh | Chief Human Resources Officer | — | female |
| Beau Standish | Chief Enabling Technologies Officer | — | — |
| Jill Mason | Chief Compliance & Risk Officer | — | female |
| Julie D. Dewey | Chief Investor Relations & Communications Officer | — | female |
| Aviva McPherron | President of Global Operations & Quality | — | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OFIX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
